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ABSTRACT 
Structural Investigation of Plasmodium falciparum Chloroquine Resistance Transporter in 
the Context of Anti-Malarial Drug Resistance 
Jonathan Kim 
 
Malaria is a mosquito borne infectious disease caused by a unicellular Apicomplexan 
parasite of the Plasmodia genus. The emergence and subsequent spread of drug resistance in the 
highly virulent Plasmodium falciparum parasite has been a major setback in eradicating malaria, 
which affects an estimated 216 million individuals and causes 445,000 deaths annually worldwide. 
Chloroquine (CQ) was once used as the first-line antimalarial drug treatment, until CQ-resistant 
parasites emerged in endemic regions including Africa, Southeast Asia, and South America. More 
recently, parasites have developed resistance to the current first line drug piperaquine (PPQ), used 
in combination with dihydroartemisinin (DHA) in Southeast Asia.  
Plasmodium falciparum chloroquine resistance transporter (PfCRT), a member of the 
drug/metabolite transporter (DMT) superfamily, is a 49-kDa integral transmembrane protein 
localized in the digestive vacuole (DV) of the pathogenic parasite. Mutations in PfCRT have been 
identified as the core determinants of Plasmodium falciparum resistance to CQ and PPQ by 
mediating the efflux of these antimalarial drugs. All CQ resistance-conferring PfCRT isoforms 
share the K76T mutation, which is widely used as a molecular marker for CQ resistance. Despite 
the significance in the impact of drug-resistant malaria, a detailed understanding of PfCRT 
physiological function and the molecular basis of PfCRT-mediated drug resistance have been 
hampered by a lack of high-resolution structural information. This dissertation describes the first 
structure of PfCRT and reveals the interaction of drugs with the purified and reconstituted protein. 
  
We determined the structure of the 49-kDa PfCRT 7G8, a clinically relevant CQ-resistant 
isoform found in South America, to 3.2 Å resolution by single-particle cryo-electron microscopy 
(cryo-EM), in complex with a specific antigen-binding fragment (Fab) to overcome current size 
limitations in cryo-EM. Our PfCRT structure displays an inward-open conformation, consists of 
10 transmembrane (TM) helices with an inverted topology, and has unique elements including two 
juxtamembrane helices and a highly conserved cysteine-rich loop between TM helix 7 and 8. The 
architecture of PfCRT is similar to other members of the DMT superfamily. TM helices 1-4 and 
6-9 in PfCRT form a central cavity which is a potential binding site for both CQ and PPQ. A 
striking feature is that virtually all the CQ resistance mutations, identified from decades of 
investigation into PfCRT variants that have evolved independently across the malaria-endemic 
world, map around this central, negatively-charged cavity. Distinct mutations that have been 
proposed to cause high-level PPQ resistance in parasites, which cause a loss of CQ resistance, 
form a planar ring that also lines this cavity. Functional experiments with various purified PfCRT 
isoforms or mutants provide evidence that drug resistance is possibly due to pH- and membrane 
potential-dependent drug transport. We also show that PfCRT CQ-resistant isoforms bind and 
transport arginine, suggesting that positively charged amino acids may be putative transport 
substrates for CQ-resistant PfCRT. This work provides a structural and functional framework to 
understand the mechanism of PfCRT-mediated drug resistance in the malaria parasite.
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Chapter 1 MALARIA: BACKGROUND AND SIGNIFICANCE 
1.1    Introduction 
Malaria is a life-threatening infectious disease that has co-evolved with humans over the 
course of history. The disease has affected an estimated 216 million individuals, 
disproportionately children, and causes 445,000 deaths annually worldwide - making it a major 
public health concern [1]. While malaria is most prevalent in sub-Saharan Africa, it also occurs 
in other endemic regions including Southeast Asia, Central, and South America (Fig. 1.1) 
[2].  Evidence of malaria fever can be found as early as 2700 BC in ancient Chinese documents, 
however, our understanding of the disease and its causes have radically shifted over the past two 
millennia. 
Initially, malaria was attributed to miasmas - foul or poisonous vapors - from swamps. In 
fact, the word malaria is derived from the medieval Italian term “mal aria”, which means "bad 
air." However, in 1676, Antonie van Leeuwenhoek's observations and discoveries of protozoa 
using a single-lensed light microscope set the pretext for new ways to understand disease from 
the emerging perspective of microbiology. In the late 1870s, Louis Pasteur and Robert Koch 
developed and provided evidence for the germ theory of disease, hypothesizing that unseen 
microorganisms were disease causing agents, and their discoveries paved the way for more 
thorough investigations into the biological causes of malaria [3]. In 1880, a French military 
physician Charles Louis Alphonse Lavern discovered various parasitic protozoans that cause 
disease in humans, including those that give rise to malaria [4]. In 1897, Ronald Ross, a British-
Indian medical scientist, found malarial parasites in the mosquito salivary gland and 
demonstrated that malarial parasites can be transmitted from mosquitoes to birds, identifying the 
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mosquito to be a vector for disease transmission [5]. At around the same time, Giovanni Battista 
Grassi, an Italian physician and zoologist, and his colleagues described the transmission of 
malaria parasite to humans [3]. These discoveries laid the groundwork for understanding the 
interactions between the parasite and mosquito vectors that affect the transmission of the malaria 
parasite into humans [6].  Today, five species of unicellular Apicomplexa parasites of the 
Plasmodium genus have been identified to infect humans and cause malaria including P. 
falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi. Among these, P. falciparum is the 
most virulent species, leading to the highest number of casualties [1]. Genetic studies have 
demonstrated that essential P. falciparum genes were highly conserved across Plasmodium 
species suggesting as the potential therapeutic targets [7-9]. 
Figure 1.1 Incidence of Malaria. The map demonstrates the number of malaria cases per 1,000 people 
across the world. Figure adapted from World Bank (https://ourworldindata.org/grapher/incidence-of-
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malaria). Among endemic regions, the highest number of malaria cases occurs in Africa (88%) followed 
by Southeast Asia (10%), Eastern Mediterranean region (2%) and Central to South America (<1%) [2]. 
1.2    The Plasmodium Life Cycle and its relationship to Human Diseases 
The transmission of Plasmodium parasites occurs when an infected female Anopheles 
mosquito bites and feeds on blood from humans, simultaneously releasing parasites in the form 
of sporozoites into the bloodstream of its new host [10]. These sporozoites migrate to the host’s 
liver within hours and rapidly invade hepatocytes. The sporozoites multiply and mature into 
merozoites, which in turn burst the hepatocytes and are released into the host’s circulatory 
system. The merozoites then invade red blood cells (RBCs) initiating a 48-hour intraerythrocytic, 
asexual cycle inside a parasitophorous vacuole (PV) (Fig. 1.2) [11]. During the asexual blood 
stage (ABS), the parasite undergoes three developing stages:  ring (0 to 24 hours post invasion), 
trophozoite (24 to 36 hours post invasion) and schizont (40 to 48 hours post invasion). At the end 
of the cycle, one merozoite has replicated into 16-32 daughter merozoites. These merozoites 
rupture the RBC membranes and are released back into circulation where each new merozoite 
infects a new RBC and repeats the cycle [12, 13]. The lysing of RBCs every 48 hours during the 
ABS cycle leads to the clinical symptoms experienced by malaria patients such as fever, chill, 
sweat and fatigue [14]. Fatalities can occur once the patient reaches hyper-parasitemia, meaning 
5% or greater of all RBCs in the body are infected, leading to hemolytic anemia. Patients can 
also develop cerebral malaria, thought to be caused by parasitized RBCs sequestered in the brain. 
Cerebral malaria leads to intracranial swelling, respiratory arrest, coma, and often death [14, 15]. 
Because the majority of disease symptoms derive from parasite replication in the ABS, all 
current anti-malarials target this point of the parasite life cycle. 
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Figure 1.2 The Plasmodium Life Cycle. (a-d) Female Anopheles mosquito releases sporozoites (the 
motile form of malaria parasite) during blood feeding. The sporozoites invade hepatocytes, maturing into 
merozoites that are then released back into circulation where they infect red blood cells (RBCs) and 
multiply as asexual blood stages (ABS) inside a parasitophorous vacuole (PV). (e-i) Sexual development 
takes approximately 10 to 12 days for the maturation of both male and female gametocytes which in turn 
are ingested by Anopheles female mosquito during blood feeding. Once in the mosquito, the gametocytes 
undergo meiotic and mitotic replication to produce 103-104 sporozoites which migrate to salivary glands 
and can infect another human host. 
While the majority of parasites in the body exist in the ABS, approximately 1-2% of 
intraerythrocytic parasites undergo a sexual development, in which they mature to male and 
female gametocytes that can be ingested by Anopheles female mosquitoes during blood feeding 
(Fig. 1.2) [11, 12]. Gametocytes are an essential bridge between the human host and the 
mosquito vector to facilitate the transmission of Plasmodium. Once ingested by the mosquito 
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host, male and female gametocytes fuse in the gut of the mosquito and undergo genetic 
recombination in the salivary glands of the mosquito, resulting in the production of sporozoites 
that can be transmitted to a new human host (Fig. 1.2).   
1.3    The Digestive vacuole 
At the start of the intraerythrocytic asexual cycle, the parasite forms a parasitophorous 
vacuole (PV) within the human red blood cell to enclose and protect it from the host immune 
system. Plasmodium exports hundreds of proteins across the parasitophorous vacuolar membrane 
(PVM) into the cytosol of host RBCs. The exported Plasmodium proteins of the malaria parasite 
interact with proteins of the RBC membrane to remodel both the morphological structure and the 
function of the host RBC to promote survival of the parasite [13, 16]. To facilitate its maturation 
within the PV, the parasite takes up a large portion of the host cell cytosol and forms an acidic 
organelle called the digestive vacuole (DV). The formation of the DV begins during the mid-ring 
stage when the cytosol of the host erythrocyte is internalized via cytostome-mediated 
invagination resulting in a double-membrane vesicles between the PVM and the plasma 
membrane (PPM) in the parasite cytosol [17]. Acidification occurs immediately, as a V-type H+-
ATPase and a H+-pyrophosphatase, transferred from the PPM to the DV membrane via 
endocytosis, begin to pump protons into the DV [17, 18]. During the trophozoite stage, the DV 
further matures and increases in size. 
A main function of the DV is to carry out the important catabolic process of hemoglobin 
(Hb) degradation. The parasite has a limited ability to synthesize its own amino acids and 
therefore must obtain these molecules from its host for protein synthesis and survival. It does this 
during the intraerythrocytic asexual stage by breaking down host Hb in the acidic environment of 
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the DV. This provides the parasite with all the essential amino acids, except isoleucine (which is 
obtained from an exogenous source in the host cell) [19, 20]. However, this essential process also 
results in a toxic by-product, free heme (or iron protoporphyrin IX), which can destabilize the 
vacuolar membrane and trigger oxidative stress [11, 21]. Heme is detoxified in the DV by 
forming the chemically inert molecule hemozoin – a crystal lattice of dimeric heme (β-hematin) 
(Fig. 1.3) [22, 23]. 
Figure 1.3 Hemoglobin degradation in the digestive vacuole of the asexual blood stage Plasmodium 
parasite. Host hemoglobin (Hb) is degraded into peptides and amino acids that are essential for parasite 
protein synthesis. Additionally, Hb produces toxic heme, which becomes detoxified via hemozin 
formation. Hb, hemoglobin; Pf, Plasmodium falciparum, PVM, parasitophorous vacuolar membrane; 
PPM, parasite plasma membrane; DV, digestive vacuole; AA, amino acids. 
1.4    Antimalarial drugs 
1.4.1 4-aminoquinolines 
Quinoline-containing chemical compounds, like quinine (QN) extracted from the 
cinchona tree, have been used for malaria treatment since the 17th century [24]. However, the 
complexity of QN production, potential side effects, and a supply shortage during World War I 
led both British and German scientists to begin developing synthetic quinoline-like substitutions 
for QN. Subsequently, 4-aminoquinolines, such as chloroquine (CQ), amodiaquine (ADQ), 
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piperaquine (PPQ) and pyronaridine (PA), and new arylamino alcohols (chemically modified 
versions of QN) including mefloquine (MQ) and lumefantrine (LMF), have led to 
more affordable, safe and efficient malaria treatments (Table 1.1). 4-aminoquinolines are 
thought to prevent the formation of hemozoin in the DV of ABS parasites, thus, inhibiting the 
detoxification of the toxic heme [11].  
Table 1.1 Features of antimalarial drugs 
1.4.2 Chloroquine 
Chloroquine (CQ), a 4-aminoquinoline drug, was first discovered in 1934 and was 
originally named Resochin by Hans Andersag and his colleagues at the Bayer laboratories. CQ 
showed minimal adverse effects during a 1943 clinical trial, and was since widely used among 
endemic regions as an affordable and effective first-line antimalarial treatment during the 1950s 
and 1960s [24].  
As a weak base, CQ freely diffuses into the acidic DV of parasites (approximately 5.3), 
where it becomes protonated and subsequently trapped within the DV. Inside the DV, di-
protonated CQ binds to reactive dimeric heme, β-hematin, and caps further growth of chemically 
inert hemozoin crystals (Fig. 1.4), causing a toxic accumulation of free heme or heme-drug 
adducts [11, 23, 25]. 
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Resistance to the former first-line CQ was first observed in the 1950s near the Thai-
Cambodian border and in South America. As resistance spread from Asia into Africa, it had a 
devastating impact with reports of up to 6–fold increases in regional malaria mortality rates [26]. 
Figure 1.4 The mechanism of 4-aminoquinoline action in the digestive vacuole (DV) of asexual 
blood stage (ABS) parasite. 4-aminoquinoline antimalarials becomes protonated in the acidic DV and 
are thought to bind heme (iron protoporphyrin IX or Fe(II)PIX) preventing its incorporation into inert 
hemozoin. AA, amino acids; ADQ, amodiaquine; CQ, chloroquine; DV, digestive vacuole; Hb, 
hemoglobin; Hz, hemozoin; Pf, Plasmodium falciparum; PfCRT, Plasmodium falciparum chloroquine 
resistance transporter; PPQ, piperaquine; RBC, red blood cell. 
1.4.3 Artemisinin-based Combination Therapies (ACTs) 
The currently available antimalarial drugs mostly target the asexual blood stage (ABS) of 
parasites as this stage is responsible for the disease symptoms. The emergence and spread of 
resistance to CQ has spurred the adoption of artemisinin-based combination therapies (ACTs) 
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since the early 2000s. ACTs consist of a fast-acting artemisinin derivative (ART) with a longer-
acting partner antimalarial drug.  
The Chinese wormwood Artemsia annua was used in treating malaria symptoms for 
hundreds of years as documented in Ge Hong’s A Handbook of Prescription for Emergencies 
which was written in approximately 300 BC [27]. Artemisinin was extracted and isolated from 
the Artemsia annua in the 1970s and has been shown to alleviate malaria fever and reduce the 
number of parasites in the blood [27]. Subsequently, other artemisinin derivatives have been 
introduced with improved stability, higher efficacy, improved oral bioavailability and a faster 
parasite clearance rate compared to the original artemisinin compound [27, 28] (Fig. 1.5). 
Artemisinin and its derivatives (ARTs) become activated once inside the ABS parasites due to 
the reductive scission of their endoperoxide bridge by heme. This activated form of artemisinin 
generates free radicals, resulting in the alkylation of biomolecules. This leads to parasite death 
due to oxidative stress and cellular damage [11, 28, 29]. The artemisinin derivatives are fast 
acting against the ABS malaria parasites resulting in rapid clearance; however, they have a short 
in vivo half-life of 1 to 3 hours in human patients [28, 30]. 
To supplement the poor pharmacokinetic properties of artemisinin and its derivatives, 
combination therapy has been implemented where ARTs are combined with a partner 
antimalarial, such as a 4-aminoquinoline or arylamino alcohol drug. The World Health 
Organization (WHO) currently recommends six different ACTs as the first line treatment 
depending on geographical resistance profile: Artesunate + amodiaquine (ASAQ); artesunate + 
mefloquine (ASMQ); artesunate + sulfadoxine-pyrimethamine (ASSP); artesunate + 
pyronaridine (PA), artemether + lumefantrine (AL); dihydroartemisinin + piperaquine (DHA-
9
PPQ) (Table 1.2). The partner drugs have longer half-lives compared to ARTs, aid in clearing 
any remaining parasites in the bloodstream, and help prevent recrudescence of disease [31]. 
Figure 1.5 Chemical structures of Artemisinin derivatives and partner drugs. Figure adapted from 
[28]. 
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Table 1.2 Current Artemisinin-based Combination Therapies (ACTs) for Clinical Use. Table 
adapted from [11]. 
ACTs have become the first-line treatment for malaria since the early 2000s. The 
incidence of malaria in the past 15 years has reduced substantially with the global adoption of 
ACTs as the first-line treatment, with mortality rates declining 60% between 2000 and 2015 
(Fig.1.6). However, artemisinin (ART) resistance has also developed over time. In recent years, 
the reduction of malaria death rate has stalled (Fig. 1.6), due mainly to parasite and Anopheles 
vector resistance. The first case of resistance to artemisinin in vivo was observed in western 
Cambodia, where a patient exhibited a prolonged parasite clearance rate [32, 33]. Sequence 
analysis studies revealed mutations in the Kelch-like protein K13 as the primary determinant of 
ART resistance [34, 35]. Although the mechanism of how individual mutations in the k13 gene 
lead to ART resistance is still unclear, the resistance mutations are thought to enhance the 
cellular response to oxidative stress caused by ART [11, 29, 35]. 
Resistance has also emerged against the partner drugs of ACTs. For example, a recent 
failure of the first-line treatment, DHA-PPQ, in Cambodia resulted from the resistance to PPQ 
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[36, 37]. The genetic analyses and studies suggest that PPQ resistance is linked to mutations in 
pfcrt [38-40] and k13 genes [41]. 
Figure 1.6 Recent reductions in the global malaria burden since 2000. Graph shows the recent 
decrease in the percentage of death rate due to malaria among different regions. Figure adapted from [1]. 
1.5    Plasmodium falciparum Chloroquine Resistance Transporter PfCRT 
In 2000, it was discovered that CQ resistant parasites had certain point mutations in a 
transmembrane protein residing on the DV membrane - a protein now known as Plasmodium 
falciparum chloroquine resistance transporter (PfCRT) [42]. PfCRT, a member of the 
drug/metabolite transporter (DMT) superfamily [43], is a 49 kDa integral membrane protein, 
consisting of 424 total amino acids, that localizes to the DV membrane of parasite in the 
trophozoite stage (Fig. 1.7). The DMT superfamily represents a large group of membrane 
transporters widely existing in eukaryotes, bacteria and archaea, and comprises 14 phylogenetic 
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families [44]. The DMT proteins maintain cellular homeostasis by exporting essential nutrients 
and metabolites including amino acids and sugars that can be detrimental at high concentrations 
[44]. Structurally, DMT superfamily proteins, including PfCRT, are predicted to have 10 
transmembrane (TM) helices [43, 44]. 
Figure 1.7 Topology of PCRT and location of residues involved in chloroquine (CQ) or piperaquine 
(PPQ) drug resistance phenotypes. Localization of PfCRT mutations associated with CQ or PPQ 
resistance. JM, juxtamembrane. 
Point mutations in PfCRT are the primary determinants of CQ and PPQ resistance and 
treatment failure (Fig. 1.7) [42, 45, 46]. Subsequent studies identified multiple PfCRT isoforms 
that have evolved in distinct geographic regions with varying drug susceptibility (Table 1.3) [39, 
47-50]. Notably, all CQ resistance conferring mutant isoforms share the K76T mutation, which
has been used as a molecular marker for CQ resistance [51]. Studies have demonstrated that CQ 
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resistant PfCRT mutants can pump CQ out of the DV into the cytosol. This proton motive-force 
dependent CQ efflux has been shown to mediate CQ resistance in the mutant parasites [52-56]. 
The inhibition of the H+-pumping V-type ATPase by concanamycin A further demonstrates that 
the efflux of CQ and proton from the DV in CQ-resistant parasites [57].    
Table 1.3 Core PfCRT haplotypes in Southeast Asia, Africa and South America. 
PfCRT is also a major determinant of Plasmodium falciparum resistance to the ACT 
partner drugs PPQ and ADQ, as well as the second-line drug quinine (QN) (Table 1.1) [38, 39, 
47, 58]. It was believed that the amplification of plasmepsins 2 and 3 which encode an Hb 
digesting protease was the mediator of resistance to PPQ [59, 60]. However, novel mutations, 
such as T93S, H97Y, F145I, I218F, M343L and G353V, have emerged from the PfCRT Dd2 
isoform in Cambodia mediating high- and low-grade resistance to PPQ used in combination with 
dihydroartemisinin (DHA) [39, 61, 62]. Interestingly, the same study further demonstrates that 
these particular mutations which increase resistance to PPQ, increase sensitivity to CQ, ADQ 
and QN, highlighting the possibility of different drug resistance mechanisms mediated by PfCRT 
among the partner drugs of ACTs [39]. In French Guiana, a novel C350R mutation in the 7G8 
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isoform has also appeared to show a similar phenotype in which the C350R mutation reverses 
the CQ hypersensitivity while conferring resistance to PPQ [63]. Moreover, PfCRT 7G8, a CQ-
resistant isoform in South America, also mediates resistance to ADQ and its active metabolite 
monodesethyl amodiaquine (MDADQ), suggesting an important driving force for selection [47, 
58]. 
The Ca2+ channel blocker verapamil (VP) reduces the efflux of CQ while enhances the 
accumulation of CQ in the DV [64]. The role of PfCRT in verapamil-reversible CQR suggests 
that PfCRT as a therapeutic target for new drugs by leveraging the resistance reversibility [50]. 
Despite of ample evidence in PfCRT as a drug transporter, our understanding on its natural 
substrate under physiological condition still remains elusive. To date, PfCRT has been proposed 
to transport amino acid, peptides and glutathione [55, 65-67].  
1.6    Significant work presented in this dissertation 
Defining the susceptibility profiles of newly emerging drug resistant PfCRT isoforms and 
predicting their impact on clinically employed antimalarials is crucial in developing effective 
treatments for malaria. However, a major limitation in our understanding of PfCRT up to date 
has been the lack of mechanistic insight into its structure and function. This information can help 
explain modes of action of CQ, PPQ, and other related antimalarial drugs, and Plasmodium 
falciparum susceptibility to them. 
The importance of PfCRT as a mediator of antimalarial drug resistance and the hope for 
developing more effective treatment to save many lives, especially children, motivated me to 
commit to this project. In this dissertation, I will present the first structure of PfCRT which 
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provides greater insight into the molecular mechanism of this key mediator of antimalarial 
resistance. 
In the next chapter, I will discuss general challenges present in the structural studies of 
membrane proteins at the current stage.  Then, I will discuss specific problems I faced during my 
thesis project and address how I overcame them. I will then present the manuscript that has been 
submitted for review recently which describes the first structure of PfCRT and reports on 
functional characterization of the protein with detailed experimental procedures. In the last 
chapter, I will present ongoing experiments to provide further explanation on how PfCRT 
mediates drug resistance, and propose future plans regarding the project.  
References 
1. World Health Organization, World Malaria Report 2018. 2018: Geneva: World Health
Organization.
2. Phillips, M.A., et al., Malaria. Nat Rev Dis Primers, 2017. 3: p. 17050.
3. Cox, F.E., History of the discovery of the malaria parasites and their vectors. Parasit
Vectors, 2010. 3(1): p. 5.
4. Nye, E.R., Alphonse Laveran (1845-1922): discoverer of the malarial parasite and Nobel
laureate, 1907. J Med Biogr, 2002. 10(2): p. 81-7.
5. Bynum, W.F., Portraits of science. Mosquitoes bite more than once. Science, 2002.
295(5552): p. 47-8.
6. Beier, J.C., Malaria parasite development in mosquitoes. Annu Rev Entomol, 1998. 43:
p. 519-43.
7. Zhang, M., et al., Uncovering the essential genes of the human malaria parasite
Plasmodium falciparum by saturation mutagenesis. Science, 2018. 360(6388).
8. Bushell, E., et al., Functional Profiling of a Plasmodium Genome Reveals an Abundance
of Essential Genes. Cell, 2017. 170(2): p. 260-272 e8.
9. Ecker, A., et al., Tricks in Plasmodium's molecular repertoire--escaping 3'UTR excision-
based conditional silencing of the chloroquine resistance transporter gene. Int J
Parasitol, 2012. 42(11): p. 969-74.
10. Bannister, L. and G. Mitchell, The ins, outs and roundabouts of malaria. Trends
Parasitol, 2003. 19(5): p. 209-13.
11. Blasco, B., D. Leroy, and D.A. Fidock, Antimalarial drug resistance: linking
Plasmodium falciparum parasite biology to the clinic. Nat Med, 2017. 23(8): p. 917-928.
16
12. Lee, A.H., L.S. Symington, and D.A. Fidock, DNA repair mechanisms and their
biological roles in the malaria parasite Plasmodium falciparum. Microbiol Mol Biol
Rev, 2014. 78(3): p. 469-86.
13. Maier, A.G., et al., Malaria parasite proteins that remodel the host erythrocyte. Nat Rev
Microbiol, 2009. 7(5): p. 341-54.
14. Hora, R., et al., Cerebral malaria--clinical manifestations and pathogenesis. Metab Brain
Dis, 2016. 31(2): p. 225-37.
15. Miller, L.H., et al., The pathogenic basis of malaria. Nature, 2002. 415(6872): p. 673-9.
16. Hiller, N.L., et al., A host-targeting signal in virulence proteins reveals a secretome in
malarial infection. Science, 2004. 306(5703): p. 1934-7.
17. Abu Bakar, N., et al., Digestive-vacuole genesis and endocytic processes in the early
intraerythrocytic stages of Plasmodium falciparum. J Cell Sci, 2010. 123(Pt 3): p. 441-
50.
18. Saliba, K.J., et al., Acidification of the malaria parasite's digestive vacuole by a H+-
ATPase and a H+-pyrophosphatase. J Biol Chem, 2003. 278(8): p. 5605-12.
19. Liu, J., et al., Plasmodium falciparum ensures its amino acid supply with multiple
acquisition pathways and redundant proteolytic enzyme systems. Proc Natl Acad Sci U S
A, 2006. 103(23): p. 8840-5.
20. Istvan, E.S., et al., Validation of isoleucine utilization targets in Plasmodium falciparum.
Proc Natl Acad Sci U S A, 2011. 108(4): p. 1627-32.
21. Goldberg, D.E., Complex nature of malaria parasite hemoglobin degradation
[corrected]. Proc Natl Acad Sci U S A, 2013. 110(14): p. 5283-4.
22. Egan, T.J., et al., Fate of haem iron in the malaria parasite Plasmodium falciparum.
Biochem J, 2002. 365(Pt 2): p. 343-7.
23. Pagola, S., et al., The structure of malaria pigment beta-haematin. Nature, 2000.
404(6775): p. 307-10.
24. Foley, M. and L. Tilley, Quinoline antimalarials: mechanisms of action and resistance
and prospects for new agents. Pharmacol Ther, 1998. 79(1): p. 55-87.
25. Combrinck, J.M., et al., Insights into the role of heme in the mechanism of action of
antimalarials. ACS Chem Biol, 2013. 8(1): p. 133-7.
26. Miller, L.H., et al., Malaria biology and disease pathogenesis: insights for new
treatments. Nat Med, 2013. 19(2): p. 156-67.
27. Tu, Y., The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat
Med, 2011. 17(10): p. 1217-20.
28. Eastman, R.T. and D.A. Fidock, Artemisinin-based combination therapies: a vital tool in
efforts to eliminate malaria. Nat Rev Microbiol, 2009. 7(12): p. 864-74.
29. Tilley, L., et al., Artemisinin Action and Resistance in Plasmodium falciparum. Trends
Parasitol, 2016. 32(9): p. 682-696.
30. White, N.J., Qinghaosu (artemisinin): the price of success. Science, 2008. 320(5874): p.
330-4.
31. Enserink, M., Malaria's drug miracle in danger. Science, 2010. 328(5980): p. 844-6.
32. Noedl, H., et al., Evidence of artemisinin-resistant malaria in western Cambodia. N Engl
J Med, 2008. 359(24): p. 2619-20.
33. Dondorp, A.M., et al., Artemisinin resistance in Plasmodium falciparum malaria. N Engl
J Med, 2009. 361(5): p. 455-67.
17
34. Ariey, F., et al., A molecular marker of artemisinin-resistant Plasmodium falciparum
malaria. Nature, 2014. 505(7481): p. 50-5.
35. Straimer, J., et al., Drug resistance. K13-propeller mutations confer artemisinin
resistance in Plasmodium falciparum clinical isolates. Science, 2015. 347(6220): p. 428-
31.
36. Amaratunga, C., et al., Dihydroartemisinin-piperaquine resistance in Plasmodium
falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis,
2016. 16(3): p. 357-65.
37. Leang, R., et al., Evidence of Plasmodium falciparum Malaria Multidrug Resistance to
Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine
Open-Label Multicenter Clinical Assessment. Antimicrob Agents Chemother, 2015.
59(8): p. 4719-26.
38. Dhingra, S.K., et al., A Variant PfCRT Isoform Can Contribute to Plasmodium
falciparum Resistance to the First-Line Partner Drug Piperaquine. MBio, 2017. 8(3).
39. Ross, L.S., et al., Emerging Southeast Asian PfCRT mutations confer Plasmodium
falciparum resistance to the first-line antimalarial piperaquine. Nat Commun, 2018.
9(1): p. 3314.
40. Agrawal, S., et al., Association of a Novel Mutation in the Plasmodium falciparum
Chloroquine Resistance Transporter With Decreased Piperaquine Sensitivity. J Infect
Dis, 2017. 216(4): p. 468-476.
41. Duru, V., et al., Plasmodium falciparum dihydroartemisinin-piperaquine failures in
Cambodia are associated with mutant K13 parasites presenting high survival rates in
novel piperaquine in vitro assays: retrospective and prospective investigations. BMC
Med, 2015. 13: p. 305.
42. Fidock, D.A., et al., Mutations in the P. falciparum digestive vacuole transmembrane
protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell, 2000.
6(4): p. 861-71.
43. Martin, R.E. and K. Kirk, The malaria parasite's chloroquine resistance transporter is a
member of the drug/metabolite transporter superfamily. Mol Biol Evol, 2004. 21(10): p.
1938-49.
44. Jack, D.L., N.M. Yang, and M.H. Saier, Jr., The drug/metabolite transporter superfamily.
Eur J Biochem, 2001. 268(13): p. 3620-39.
45. Djimde, A., et al., A molecular marker for chloroquine-resistant falciparum malaria. N
Engl J Med, 2001. 344(4): p. 257-63.
46. Sidhu, A.B., D. Verdier-Pinard, and D.A. Fidock, Chloroquine resistance in Plasmodium
falciparum malaria parasites conferred by pfcrt mutations. Science, 2002. 298(5591): p.
210-3.
47. Sa, J.M., et al., Geographic patterns of Plasmodium falciparum drug resistance
distinguished by differential responses to amodiaquine and chloroquine. Proc Natl Acad
Sci U S A, 2009. 106(45): p. 18883-9.
48. Callaghan, P.S., M.R. Hassett, and P.D. Roepe, Functional Comparison of 45 Naturally
Occurring Isoforms of the Plasmodium falciparum Chloroquine Resistance Transporter
(PfCRT). Biochemistry, 2015. 54(32): p. 5083-94.
49. Petersen, I., et al., Balancing drug resistance and growth rates via compensatory
mutations in the Plasmodium falciparum chloroquine resistance transporter. Mol
Microbiol, 2015. 97(2): p. 381-95.
18
50. Ecker, A., et al., PfCRT and its role in antimalarial drug resistance. Trends Parasitol,
2012. 28(11): p. 504-14.
51. Lakshmanan, V., et al., A critical role for PfCRT K76T in Plasmodium falciparum
verapamil-reversible chloroquine resistance. EMBO J, 2005. 24(13): p. 2294-305.
52. Bray, P.G., et al., Defining the role of PfCRT in Plasmodium falciparum chloroquine
resistance. Mol Microbiol, 2005. 56(2): p. 323-33.
53. Paguio, M.F., M. Cabrera, and P.D. Roepe, Chloroquine transport in Plasmodium
falciparum. 2. Analysis of PfCRT-mediated drug transport using proteoliposomes and a
fluorescent chloroquine probe. Biochemistry, 2009. 48(40): p. 9482-91.
54. Zhang, H., M. Paguio, and P.D. Roepe, The antimalarial drug resistance protein
Plasmodium falciparum chloroquine resistance transporter binds chloroquine.
Biochemistry, 2004. 43(26): p. 8290-6.
55. Martin, R.E., et al., Chloroquine transport via the malaria parasite's chloroquine
resistance transporter. Science, 2009. 325(5948): p. 1680-2.
56. Juge, N., et al., Plasmodium falciparum chloroquine resistance transporter is a H+-
coupled polyspecific nutrient and drug exporter. Proc Natl Acad Sci U S A, 2015.
112(11): p. 3356-61.
57. Lehane, A.M., et al., A verapamil-sensitive chloroquine-associated H+ leak from the
digestive vacuole in chloroquine-resistant malaria parasites. J Cell Sci, 2008. 121(Pt 10):
p. 1624-32.
58. Gabryszewski, S.J., et al., Combinatorial Genetic Modeling of pfcrt-Mediated Drug
Resistance Evolution in Plasmodium falciparum. Mol Biol Evol, 2016. 33(6): p. 1554-70.
59. Amato, R., et al., Genetic markers associated with dihydroartemisinin-piperaquine
failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype
association study. Lancet Infect Dis, 2017. 17(2): p. 164-173.
60. Witkowski, B., et al., A surrogate marker of piperaquine-resistant Plasmodium
falciparum malaria: a phenotype-genotype association study. Lancet Infect Dis, 2017.
17(2): p. 174-183.
61. van der Pluijm, R.W., et al., Determinants of dihydroartemisinin-piperaquine treatment
failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a
prospective clinical, pharmacological, and genetic study. Lancet Infect Dis, 2019.
62. Hamilton, W.L., et al., Evolution and expansion of multidrug-resistant malaria in
southeast Asia: a genomic epidemiology study. Lancet Infect Dis, 2019.
63. Pelleau, S., et al., Adaptive evolution of malaria parasites in French Guiana: Reversal of
chloroquine resistance by acquisition of a mutation in pfcrt. Proc Natl Acad Sci U S A,
2015. 112(37): p. 11672-7.
64. Krogstad, D.J., et al., Efflux of chloroquine from Plasmodium falciparum: mechanism of
chloroquine resistance. Science, 1987. 238(4831): p. 1283-5.
65. Lewis, I.A., et al., Metabolic QTL analysis links chloroquine resistance in Plasmodium
falciparum to impaired hemoglobin catabolism. PLoS Genet, 2014. 10(1): p. e1004085.
66. Ginsburg, H., et al., Inhibition of glutathione-dependent degradation of heme by
chloroquine and amodiaquine as a possible basis for their antimalarial mode of action.
Biochem Pharmacol, 1998. 56(10): p. 1305-13.
67. Patzewitz, E.M., et al., Glutathione transport: a new role for PfCRT in chloroquine
resistance. Antioxid Redox Signal, 2013. 19(7): p. 683-95.
19
Chapter 2 MEMBRANE PROTEIN STRUCTURE 
2.1 Membrane protein: Introduction 
Membrane proteins, including transporters, pumps, enzymes, receptors and channels, play 
important roles in many fundamental biological processes. They are essential in maintaining the 
structural integrity of the cell membrane, relaying signals between the extracellular and 
intracellular environment, and transporting small molecules and ions across the cell membrane 
facilitating the maintenance of cellular homeostasis. Membrane proteins constitute approximately 
22% of the human proteome, and approximately 60% of current drug targets are membrane 
proteins [68].  
Despite their relevance as therapeutic targets for various human diseases, our knowledge 
of membrane protein structures is still scarce. In fact, only approximately 900 unique membrane 
protein structures have been determined up to date (Fig. 2.1; 
https://blanco.biomol.uci.edu/mpstruc/; data retrieved on June 3, 2019) from the total predicted 
31,778 genes encoding for membrane proteins [69]. Thus, less than 3% of the unique structures 
of membrane proteins are currently available in the Protein Data Bank (PDB, 
https://www.rcsb.org) and much remains to be discovered. 
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Figure 2.1 Membrane protein structural determination over time. The graph was adapted from 
Stephen White’s Membrane Proteins of Known Structures Database 
https://blanco.biomol.uci.edu/mpstruc/; data retrieved on June 3, 2019. 
The first three-dimensional projection structure of bacteriorhodopsin from Halobacterium 
halobium was determined at 7Å resolution using electron crystallography on two-dimensional 
crystals in 1975 by Richard Henderson and Nigel Unwin [70]. The first atomic-resolution 
structure of a membrane protein, the photosynthetic reaction center purified from 
Rhodopseudomonas viridis, was solved to 3Å resolution using x-ray crystallography in 1985 
[71]. Since then, the advancements in the three major techniques for structural studies – x-ray 
crystallography, electron microscopy (EM) and nuclear magnetic resonance (NMR) – have been 
accelerating the progress of structural biology of membrane proteins (Fig 2.1). Over the years the 
most predominant technique for structural studies of membrane proteins has been x-ray 
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crystallography, and the majority of membrane protein structures deposited in the PDB are 
determined by using x-ray crystallography [72]. Recent technological advancements in the field 
of single-particle cryogenic electron microscopy (cryo-EM) has further facilitated new pathway 
for structural determination of selective classes of proteins. However, cryo-EM is still not 
suitable for solving small molecules (i.e. < 100 kDa) to high resolution. 
Despite of the exponential growth in the number of structures solved, sample preparation 
still remains a major bottleneck in membrane protein structural studies. Membrane proteins 
generally have low expression levels in cells and/or heterologous systems. Moreover, eukaryotic 
membrane proteins often require eukaryotic host cells such as yeast, insect cells and mammalian 
cells [73]. The low abundance of membrane proteins makes it extremely difficult for structural 
analysis. Furthermore, the hydrophobic nature of membrane proteins within lipid bilayers often 
further complicates structure determination. Structural and functional studies of membrane 
protein require the protein to be extracted from the lipid bilayer and further solubilized and 
purified in the presence of surfactants like detergents. However, many detergents and their 
micelles are harsh for protein stability, as proteins can be misfolded once extracted from their 
native lipid environments leading to denaturation or aggregation. In x-ray crystallography, 
detergents and their micelles can hamper the ability of protein to be crystalized as they mask the 
transmembrane (TM) region and minimize the surface area for protein-protein crystal contacts. 
Also, detergents can be problematic in cryo-EM analysis as free empty detergent micelles tend to 
diminish the contrast of protein in cryo-EM images [74, 75]. Therefore, the choice of the 
appropriate detergent appears to be a challenge throughout all the steps towards membrane 
protein structure determination. 
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2.2 Structural Determination Technique: Single-Particle Cryo-Electron Microscopy 
(Cryo-EM)  
In the past, the electron microscopy approach for structural determination of protein was 
limited by low resolution. Cryo-EM enables us to provide three-dimensional structural 
information of biological macromolecules by averaging EM images of non-crystalline specimens 
embedded in a thin layer of vitreous ice in random orientations [76]. A beam of electrons, as the 
source of illumination, transmits through a sample and projects an image [77]. The series of two-
dimensional images from sample particles in the same orientation are averaged computationally 
and are further used to provide a three-dimensional electron density map [78]. Recent 
improvements in camera and data processing software packages together have led to the 
“resolution revolution” in cryo-EM [79]. Such improvements have allowed to determine 
structures of integral membrane proteins that had previously been intractable with x-ray 
crystallography including for example Transient receptor potential channel (TRPV1) [80], 
Stimulated by Retinoic Acid 6 (STRA6) [81] and Ryanodine receptors (RyRs) [82]. In the 
following sections, I will discuss the basic workflow of single-particle cryo-EM. 
2.2.1 Sample preparation 
One advantage of cryo-EM analysis over x-ray crystallography is that cryo-EM does not 
require a large quantity of homogeneous sample, which is a critical, yet, challenging parameter 
for crystallization and the need of crystals. Once a purified sample is obtained, negative stain EM 
is usually the first step to examine and screen the quality of target protein sample. It can also be 
used to reconstruct a low-resolution three-dimensional structure [83]. For negative stain, the 
sample is applied onto a carbon coated grid and stained with heavy metal salts like uranyl 
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formate or uranyl acetate, which readily interact with the electron beam to enhance phase 
contrast. The issue with negative stain is that the resolution is limited by the size of the heavy 
metal grains approximately to 15 Å. 
2.2.2. Sample Vitrification 
To obtain high resolution reconstructions, the sample is required to undergo a 
vitrification step for cryo-EM analysis. Vitrification is a crucial step, as it helps maintaining the 
specimen intact in the native orientation from the radiation damage in the electron microscope 
[84]. The protein sample is applied onto a holey carbon or gold grid, excess liquid is blotted 
away, and the sample is immediately plunged into liquid ethane cooled by liquid nitrogen, to 
approximately -160 °C, to create a thin layer of vitrified ice [85, 86]. Ice thickness is critical, as a 
consistent thin layer of ice on the grid helps establish high contrast between the protein particles 
and the ice background and also avoid possible defocus problems caused by the different heights 
of particles in the ice layer [76]. Currently, the commercially available automated plunge-freezer 
instruments, such as Leica EM GP, Vitrobot™, Cryoplunge™, are designed to produce a thin 
and reproducible vitrified ice layer, and variables like humidity, temperature and blotting time 
can be changed and optimized as needed for each sample [87]. 
2.2.3 Imaging 
Vitrified samples in different cryogenic conditions are required to screen on a low-end 
microscope which provides information on sample particle distribution and ice thickness. The 
grid with the optimal cryogenic condition then can be imaged on a high-end microscope 
equipped with 200 kV or 300 kV acceleration voltage and a field emission gun (FEG) electron 
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source producing an electron beam with more penetrance and coherence [88]. Recent 
introduction of the direct electron detector device (DDD) camera [89] and beam-induced motion 
correction [90] helped improve EM image quality. Compared to previous technologies, the DDD 
camera provides enhanced detective quantum efficiency (DQE), a measure of signal and noise 
performance in an image with a function of spatial frequencies, to improve the signal-to-noise 
between sample particles and background. Also, the camera has the capability to record high 
frame rate movies instead of a single micrograph while correcting beam-induced movement and 
image blurring to enhance the sharpness of the particle images [89]. Such developments and 
improvements in camera have made it possible to produce a good quality of images and 
ultimately obtain a high-resolution density map. 
2.2.4 Reconstruction 
Determining a high-resolution 3D reconstruction requires 2D projection images. Particle 
picking from each micrograph can often be difficult as the image has low contrast and noise. The 
particle picking can be achieved either manually, automated, or semi-automated with templates. 
Particles in the same conformation are aligned, clustered and averaged together to enhance the 
signal to noise ratio in generating 2D projection images of particles [77]. A 3D reconstruction of 
the sample can be achieved by using the projection slice theorem, which combines the 2D 
Fourier transform of the 2D projection of electron densities from all angles followed by an 
inverse Fourier transform in 3D. When the particle images of a 3D reference in all projection 
directions are converged during the refinement, the final reconstruction is made through back 
projection of the 2D particles [91, 92](Fig. 2.2). Recent developments in data processing 
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algorithms and software packages such as RELION [93] and cryoSPARC [94] have provided 
convenient ways to proceed in the 3D reconstruction of protein sample from the cryo-EM data. 
Figure 2.2 Structure determination workflow by single particle cryo-EM. Initial low resolution 2D 
classes can be obtained by negative stain EM. The purified protein sample can be frozen on grids for 
cryo-EM analysis. Micrographs are collected as a subframe movie, which is further aligned and averaged. 
Particles are picked from each image, aligned and clustered in the same spatial orientation and used to 
reconstruct a 3D structure. 
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Chapter 3 STRUCTURAL ELUCIDATION OF PfCRT 7G8 
3.1 Introduction 
As described in Section 1.5, PfCRT is a 49-kDa transporter spanning the membrane of 
the pathogenic intra-erythrocytic asexual blood stage (ABS) parasite’s digestive vacuole and is 
responsible for resistance to both previously and currently used first-line antimalarials. Despite 
its importance both physiologically and clinically, further insight into PfCRT function and 
structure, and the molecular basis of PfCRT-mediated drug resistance, have been hampered by 
the lack of an atomic model. Structural information of PfCRT will help elucidate respective drug 
binding and drug resistance mechanisms and provide basis for the development of future 
therapies.   
In this chapter, I will describe steps and approaches developed to overcome the 
challenges mentioned in Chapter 2 in determining a structure of PfCRT. I believe that the work 
detailed in the following sections represents a significant advance in understanding the molecular 
mechanisms underlying Pf resistance to antimalarial drugs in clinical use. Furthermore, 
determining the structure of a sub-50kDa membrane protein by cryo-EM is a noteworthy 
achievement. 
Prior to presenting the manuscript which describes the first structure of PfCRT, I will 
briefly discuss the experimental procedures involving the optimization of PfCRT expression, 
stability, and purity. 
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3.2 Expression Screen of Chloroquine Resistance Transporter (CRT) Variants 
The expression of PfCRT has been a long-standing problem in both structural and 
functional studies [95]. To overcome this crucial barrier, we used a structural genomics approach 
in which we screened for optimal expression of PfCRT variants with different drug resistance 
profiles, isoforms from different Plasmodia, or codon optimized for different organisms and 
expression systems (Fig. 3.1 and Table 3.1) [96]. We generated C-terminal GFP fusion 
constructs with a decahistidine affinity tag and screened them first for expression by western 
blot, and then for stability in detergent (dodecyl-maltoside; DDM) by fluorescence coupled size-
exclusion chromatography (FSEC) (Fig. 3.2) [97]. These experiments allowed us to identify the 
PfCRT 7G8 CQ-resistant isoform as a candidate for structural investigation. 
Figure 3.1 Schematic representation of COMPPÅ pipeline. Structural genomics method was adapted 
from the Center on Membrane Protein Production and Analysis (COMPPÅ) pipeline. The expression of 
target protein and its variants are screened in high throughput manner to identify the most promising 
target for further structural and functional studies. FSEC, fluorescence coupled size-exclusion 
chromatography. 
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Table 3.1 CRT variants cloned and tested for expression. 
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Figure 3.2 Expression and detergent stability screens of CRT variants. (left) anti-GFP western blot, 
where the molecular weight for CRT GFP fusion is marked by a yellow asterisk. Lanes are: 1 empty 
vector, 2 positive control (D. rerio STRA6), 3 MW markers, 4 PfCRT HB3, 5 PfCRT Dd2, 6 PfCRT HB3 
codon optimized for X. laevis, 7 PfCRT Dd2 codon optimized for X. laevis, 8. Theileria annulata ANKA 
CRT, 9 Cryptosporidium parvum Iowa II CRT, 10 P. vivax Sal-1 CRT, 11 PfCRT 7G8, 12 P. vivax Sal-1 
CRT codon optimized for Sf9 cells. (right) FSEC DDM elution profiles for the positive control (D. rerio 
STRA6), HB3, Dd2 and 7G8 PfCRT. 
The expression of PfCRT 7G8 was tested in various systems including baculovirus 
infection of insect cells, transient transfection of mammalian cells with polyethylenimine (PEI) 
[98], and baculovirus transduction of mammalian cells (BacMam system). Based on the protein 
yield, the BacMam system was used for further optimization. The BacMam system employs a 
modified insect baculovirus, encoding the target gene of interest, to transduce HEK293 cells 
lacking N-acetylglucosaminyltransferase I (GnTi-) where the constitutively active CMV 
promoter drives expression [99, 100]. Also, the addition of a histone deacetylase inhibitor like 
sodium butyrate in the BacMam system was used to enhance protein expression [99].  
To test and optimize the expression level of PfCRT 7G8 isoform with the BacMam 
system, I transduced 100 mL HEK293 GnTi- cells at 2.0 million cells per mL with a fixed 
amount of virus (1:10 v/v between virus to culture) varying three conditions: temperature after 
the addition of 10 mM sodium butyrate (30 °C and 37 °C), time point on the addition of 10 mM 
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sodium butyrate post transduction (8 hours versus 24 hours), and time point on harvest (2 days 
versus 3 days). Cell pellets of each condition were solubilized in DDM, nickel purified, and 
loaded on an analytical Superdex 200 Increase 5/150 GL column (GE Healthcare) for high 
performance liquid chromatography (HPLC). The condition at 37 °C, sodium butyrate 8 hours 
after transduction, and harvest after 2 days produced the highest yield of protein (Fig. 3.3). 
Subsequently, I was able to obtain 0.4-0.6 mg of PfCRT 7G8 per 800mL of transduced cells. The 
enhanced expression of PfCRT was instrumental in allowing us to screen further purification 
conditions.  
Figure 3.3 PfCRT 7G8 expression optimization. Small-scale cultures of cells were transduced with 
fixed amount of baculovirus and 10 mM sodium concentration. The time of sodium butyrate addition was 
tested at 8 h or 24 h post transduction at two temperature points (30 °C or 37 °C) upon the addition of 
sodium butyrate. The harvest time after the addition of sodium butyrate was tested between 2 days or 3 
days. The nickel purified sample of each condition was loaded and evaluated by an analytical gel 
filtration column Superdex 200 Increase 5/150 with high performance liquid chromatography (HPLC). 
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3.3 Detergent and Stability Screen of PfCRT 7G8 
The initial expression and stability screen shown in Section 3.2 was performed using the 
nonionic detergent, dodecyl-maltoside (DDM), which is a mild detergent that is commonly used 
to extract and solubilize membrane proteins. To find more stable purification conditions for 
PfCRT 7G8, other detergents were examined in the absence or presence of cholestryl 
hemisuccinate (CHS). CHS has been shown to improve the stability of G protein-coupled 
receptors and has been commonly used in stabilizing membrane proteins during purification 
[101]. The nickel purified samples were loaded on to an analytical Superdex 200 Increase 5/150 
GL column (GE Healthcare) for gel filtration on HPLC. The screen results demonstrate a 
substantial improvement in stability of PfCRT 7G8 in DDM with the addition of CHS (Fig. 3.4). 
Therefore, DDM/CHS (10:1 w/w) was used for the remaining of the experiment. This result was 
consistent with a recently published paper on the purification of truncated PfCRT HB3 CQ-
sensitive isoform [102]. 
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Figure 3.4 Detergent Screen for PfCRT 7G8. Nickel purified samples in various detergents were 
evaluated by an analytical gel filtration column (Superdex 200 Increase 5/150 GL column) on high 
performance liquid chromatography (HPLC). Cholestryl hemisuccinate (CHS); DDM n-Dodecyl-β-D-
Maltopyranoside; LMNG Lauryl Maltose Neopentyl Glycol and Digitonin. The optimal condition is 
bolded in the legend. 
3.4 Reconstitution of PfCRT 7G8 into Nanodiscs 
Once the expression and stability of the PfCRT 7G8 in DDM/CHS had been optimized, 
initial attempts to crystallize the PfCRT 7G8 were performed. However, when we attempted to 
concentrate the purified sample beyond 2mg/mL, the protein was unstable in detergent solution 
and precipitated, which made setting up trays for crystallization challenging. Additionally, the 
level of purity, based on SDS-PAGE gel analysis, after metal affinity chromatography followed 
by size exclusion chromatography in buffer containing detergent, was not optimal for 
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nanodiscs. Nanodiscs consist of two copies of amphipathic membrane scaffolding proteins 
(MSP) encircling a target protein embedded in a bilayer of phospholipids [103]. The nanodiscs 
mimic a native lipid bilayer environment, in which the protein is more stable, soluble and 
provides homogenous particles of defined size and composition. A second metal affinity 
chromatography step was introduced after the reconstitution into nanodiscs in order to remove 
excess free empty nanodisc and further improve sample purity (Fig. 3.5).  In result, the 
reconstitution of PfCRT 7G8 into nanodiscs enhanced both purity and stability (data shown in 
the manuscript Extended Data Fig. 2) 
Figure 3.5 Schematic representation of nanodisc assembly. Nanodiscs assembly requires a target 
membrane protein to be extracted from native lipid bilayers in the presence of detergent, to which 
membrane scaffold proteins (MSP) and phospholipids are added into purified protein in solution 
containing detergent. Detergent is removed upon the addition of bio-beads while protein is incorporated 
into nanodisc bilayers. Figure adapted from https://www.labome.com/method/Nanodiscs-Membrane-
Protein-Research-in-Near-Native-Conditions.html. 
3.5 Structural Elucidation of PfCRT 7G8 
As an alternative to x-ray crystallography, we used cryo-EM to determine the structure of 
PfCRT 7G8. The primary challenge in solving the PfCRT structure using cryo-EM was that the 
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size of the protein (49kDa) is well below the average size of macromolecules amenable for cryo-
EM analysis despite recent advances in the field. Also, based on protein structure predictions the 
majority of protein was anticipated to be embedded in the lipid bilayer [43], and a lack of soluble 
features would make it difficult to align particles in cryo-EM analysis. To overcome these 
challenges, we collaborated with the Kossiakoff laboratory at the University of Chicago to raise 
and select 50-kDa antigen-binding fragments (Fab) which bind specifically to PfCRT to increase 
the size of the protein particle and to provide soluble features to help particle alignment in cryo-
EM analysis. We reconstituted PfCRT 7G8 into biotinylated nanodiscs and sent the sample off to 
the Kossiakoff laboratory. The Kossiakoff laboratory has developed a technique where they 
screen a phage display library to select a Fab that binds to the target protein with high affinity 
[104]. Subsequently, 4 Fab candidates were obtained for complex formation. Based on the 
binding affinity, which was determined using ELISA (data shown in the manuscript Extended 
Data Fig. 2), I chose the 7G8-CTC Fab as it has the highest affinity. I further confirmed that 
PfCRT 7G8 and the CTC Fab form a stable complex using size exclusion chromatograph and 
negative stain EM (data shown in the manuscript Extended Data Fig. 2 and 3).  
I will now present the manuscript “Structure of the Plasmodium falciparum Pleiotropic 
Drug Resistance Transporter PfCRT”, that is currently under review in Nature. This manuscript 
demonstrates for the first time the structure of PfCRT and provides greater insight into where 
antimalarial drugs (CQ and PPQ) might bind. Also, we show the location of clinical mutations 
causing drug resistance in our structural model, and further reveal that PfCRT transports drug in 
the presence of both a membrane potential and a pH gradient. Finally, we propose that arginine is 
a potential substrate for CQ-resistant isoforms of PfCRT under physiological conditions.  
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Summary: The emergence and spread of drug-resistant Plasmodium falciparum has been a 
major setback in efforts to control and eliminate malaria. For decades, treatment relied on 
chloroquine (CQ), a safe and affordable 4-aminoquinoline that was highly effective against 
pathogenic intra-erythrocytic asexual blood-stage (ABS) parasites until resistance arose and 
spread, with devastating consequences in Africa1. Resistance to the chemically related current 
first-line combination drug piperaquine (PPQ) has also recently emerged, thwarting its treatment 
efficacy in Southeast Asia. Resistance to both CQ and PPQ has been associated with distinct sets 
of point mutations in the 49 kDa P. falciparum chloroquine resistance transporter PfCRT2, a 
member of the drug/metabolite transporter (DMT) superfamily3, which resides within the 
digestive vacuole (DV) membrane of the parasite. Here we present the structure of the PfCRT 
CQ-resistant, PPQ-sensitive 7G8 isoform to 3.2 Å resolution, determined using fragment 
antigen-binding technology and single-particle cryo-electron microscopy. Mutations contributing 
to resistance to CQ and PPQ map to a central cavity, implicating this as the major site of drug 
interaction. Binding and transport studies reveal that the 7G8 isoform binds both drugs, and 
mediates transport of CQ and of the positively charged amino acid arginine in a membrane 
potential- and pH-dependent manner. These data provide the first atomic-level insights into the 
molecular mechanism of this key mediator of antimalarial treatment failures. 
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Recent reductions in the global malaria burden have stalled in the past 2-3 years, with the 
situation in Southeast Asia exacerbated by emerging resistance to artemisinin-based combination 
therapies including the bis-4-aminoquinoline partner drug PPQ4-6. A major determinant of drug 
resistance in Plasmodium falciparum malaria parasites is the 49 kDa putative transporter PfCRT. 
Amino acid substitutions in this protein group as haplotypes that originated independently 
decades ago in several regions subjected to intense drug pressure with the former gold-standard 
antimalarial, CQ. These include the 5-amino acid 7G8 variant that dominates in South America 
and the Western Pacific, and the 8-amino acid Dd2 variant that is prevalent in Southeast Asia 
and that is thought to have seeded the introduction of mutant PfCRT and CQ resistance into 
Africa (Extended Data Fig. 1). Extensive use of PPQ in Cambodia is suspected to have recently 
driven the rapid emergence of novel PfCRT mutations, arising in the Dd2 isoform7. For CQ, 
resistance has been attributed to mutant PfCRT-mediated efflux of drug out of the DV (Fig. 1a). 
It remains unclear whether this mechanism would apply to PPQ8-12. CQ and PPQ are thought to 
act by accumulating in the ABS parasite’s acidic DV as protonated species that bind toxic Fe3+ 
heme (ferri-protoporphyrin IX; FPIX) and inhibit heme incorporation into chemically inert 
hemozoin crystals13, 14. FPIX is released following parasite-mediated proteolysis of host 
hemoglobin (Hb) that is endocytosed into the DV. 
To explore the structural basis of PfCRT-mediated drug resistance, we used single-particle cryo-
electron microscopy (cryo-EM) to determine the structure of the 49 kDa 7G8 PfCRT. To 
overcome current cryo-EM size limitations15, we screened a synthetic phage display library16 to 
select for recombinant PfCRT-specific antigen-binding fragments (Fabs, ~50 kDa) to form a 
stable PfCRT-Fab complex (Extended Data Fig. 2 and 3). The cryo-EM reconstruction of the 
nanodisc-incorporated 7G8 PfCRT-Fab complex was determined to a nominal resolution of 3.3 
Å, with the PfCRT portion resolved to 3.2 Å (Extended Data Table 1 and Extended Data Fig. 
4). Using this map, a de novo model of PfCRT was built comprising residues 47-113 and 123-
405 of the 424-amino acid protein (Fig. 1b, c and Extended Data Fig. 4, 5). PfCRT is 
monomeric and consists of 10 transmembrane (TM) helices with both termini located on the 
cytosolic side (Fig. 1b). Two juxtamembrane helices (JM1 and JM2), parallel to the DV 
membrane on opposite sides, are located at the N-terminus and between TM helices 7 and 8, 
respectively (Fig. 1b). The 10 TMs are arranged as five helical pairs that form two-helix hairpins 
with an inverted topology, whereby the N-termini of helices 1-5 pair on the same side of the DV 
membrane as the C-termini of helices 6-10 (Fig. 1b, c and Extended Data Fig. 6). The structure 
of PfCRT is similar to Vrg4 (PDB ID: 5OGE/5OGK;17), YddG (PDB ID: 5I20;18) and TPT (PDB 
ID: 5Y78/5Y79;19), which are also DMTs (Extended Data Fig. 7A).  
TM helices 1–4 and 6–9 form a central cavity of ~ 3,300 Å3 that is wider on the DV side of the 
protein and closes approximately halfway into the membrane, suggesting that the structure is in 
an open-to-DV/inward-open state conformation (Fig. 2a). The corresponding cavity in Vrg4, 
TPT and YddG constitutes the known ligand-binding site (Extended Data Fig. 7b), predicting 
that this cavity is also the ligand-binding site for PfCRT. The net charge in the PfCRT cavity is 
negative, determined mainly by the aspartate residues D137, D326 and D329 (Fig. 2a). In 
contrast, both Vrg4 and TPT have a positively charged cavity, whereas that of YddG is neutral 
(Extended Data Fig. 7b). These electrostatic profiles suggest that putative substrates for PfCRT 
are likely positively charged, in contrast to those of the other three DMTs cited. Consistent with 
41
this proposal, the positively charged residue arginine R111 in the variable loop region of our 
selected Fab occupies the predicted binding site in the cavity of PfCRT (Fig. 2b). Interactions 
between the Fab R111 and PfCRT D326 and D329 presumably help stabilize the PfCRT-Fab 
complex (Fig. 2b).  
Alignment of the PfCRT sequence with Plasmodia and other Apicomplexan orthologs reveals 
extensive sequence conservation within the helices that line the cavity, as well as the adjacent 
TM5 / TM10 inverted helices that are separate from the cavity (Fig. 2c and Extended Data Fig. 
8). None of the PfCRT mutations associated with CQ or PPQ resistance mapped to residues that 
were fully conserved across our set of Apicomplexan CRT orthologs (Extended Data Fig. 8), 
suggesting structural and/or functional constraints. We also identified density in a separate cleft 
region, delineated by JM1, TM1, TM9 and TM10, near the cytosolic side of the DV membrane. 
We tentatively assigned this density to cholesterol hemisuccinate, present during the purification 
(Extended Data Fig. 9). This hydrophobic cleft is absent in the other DMT superfamily 
members cited above, which also lack JM1.  
Extensive conservation was also observed in JM2 and the ensuing long loop connecting TM 
helices 7 and 8. This loop, extending into the DV, consists of four highly conserved cysteines 
that likely form two disulfide bridges (Fig. 2c, d and Extended Data Fig. 8), suggesting that 
this particular region might be involved in redox sensing through formation of reversible 
disulfide bonds20. A role for PfCRT in redox sensing is plausible given the release in the acidic 
DV (pH 5.2-5.5) of Hb-derived Fe2+-protoporphyrin IX, whose oxidation to the Fe3+ state 
produces reactive oxygen species21.  
The structure of PfCRT provides key insights into how mutations can confer resistance to CQ 
and PPQ (Fig. 3a). All CQ-R isoforms, irrespective of geographic origin, share a common and 
requisite K76T mutation, substituting a positive lysine that is believed to repel CQ2+ for an 
uncharged threonine9, 22. Our structure places residue 76 directly in the lining of the central 
cavity (Fig. 3b). The CQ-R 7G8 isoform has four additional mutations (C72S, A220S, N326D, 
I356L; compared with the canonical wild-type CQS 3D7 isoform), which also line the cavity 
(Fig. 3b), supporting this region as the primary site of CQ interactions. Indeed, this cavity, with a 
~25Å maximum diameter, is in principle able to accommodate CQ or PPQ (~14 and ~21Å 
maximum lengths, respectively). The C350R mutation, which reverses CQ resistance when 
added to 7G823, also resides in this cavity where presumably the introduction of the positive Arg 
residue minimizes interactions with CQ2+. Similarly, the CQ-R Dd2 isoform has six (M74I, 
N75E, K76T, A220S, N326S, I356T) of its eight mutations located within the cavity, with two 
additional mutations (Q271E and R371I) located at its entrance (Fig 3b and Extended Data Fig. 
1b).  
Our structural data support a primary role for PfCRT in PPQ resistance, with the associated 
amino acid substitutions lining the cavity (including C350R that arose on the 7G8 isoform; as 
well as H97Y, F145I, and G353V that emerged on the Dd2 isoform; Fig. 3b). The high-grade 
resistance mutation F145I resides close to the cavity entrance, and both H97Y and G353V are in 
line with the plane of CQ-R mutations. M343L, which confers low-grade PPQ resistance in the 
Dd2 isoform, lies above the cavity, close to the cytosol. Almost all mutations that promote PPQ 
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resistance in Dd2 parasites result in at least some loss of CQ resistance, suggesting differences in 
CQ and PPQ binding and transport (Fig. 3b and Extended Data Fig. 1a;7).  
Using scintillation proximity-based assays24 on structurally-validated purified protein 
reconstituted in nanodiscs, we found that PfCRT 7G8 binds both CQ and PPQ (Fig. 4a). Isotopic 
dilution assays yielded mean half-maximal binding constants of ~300 nM for CQ, similar to 
earlier studies with Dd2 PfCRT25, 26, and ~190 nM for PPQ (Fig. 4b). Each drug competitively 
inhibited the binding of the other with virtually identical mean half-maximal inhibition constants 
(IC50 values) of ~170 nM (Fig. 4c).  
Binding of these two drugs was partially inhibited by verapamil (Fig. 4d), a known CQ 
resistance reversal agent that has been reported to inhibit CQ transport by resistant parasites27. 
Near-complete inhibition was observed with amodiaquine, a related 4-aminoquinoline first-line 
partner drug against which PfCRT 7G8 mediates cross resistance28, implying similar drug 
occupancies in the PfCRT cavity. Control assays found no inhibition for [3H]-CQ or [3H]-PPQ 
binding with the structurally unrelated antimalarial drugs lumefantrine and atovaquone that have 
separate modes of action. No [3H]-CQ or [3H]-PPQ binding was observed with the unrelated 
transporter LeuT29.  
We also examined drug uptake using protein reconstituted in proteoliposomes, which allowed us 
to investigate energetic requirements for transport. Our data showed that active [3H]-CQ uptake 
required an inwardly directed pH gradient (pH 5.5-7.5, corresponding to the gradient observed in 
the DV of the parasites30), and a membrane potential rY (Extended Data Fig. 10a). Here, rY 
was created by an outward-directed K+ diffusion gradient from the proteoliposomes in the 
presence of the K+-specific ionophore valinomycin. Using these conditions, we observed [3H]-
CQ uptake, peaking within one minute (Fig. 4e). These results support proton motive force-
dependent CQ efflux as the mechanism underlying mutant PfCRT 7G8-mediated CQ resistance, 
and are consistent with earlier reports10-12, 25, 27, 31. Under our experimental conditions, no 
detectable uptake was observed with [3H]-PPQ, as expected for this PPQ-S isoform (Fig. 4e).  
Based on the observed interaction between the Fab R111 and the cavity of PfCRT (Fig. 2b), 
earlier evidence that mutant PfCRT isoforms can result in excess accumulation of Hb-derived 
peptides in the DV32, 33, the cationic nature of putative PfCRT substrates, and prior transport 
studies34, we also tested the inhibition of Arg on [3H]-CQ binding. Indeed, this positively 
charged amino acid inhibited [3H]-CQ binding, whereas control experiments using Leu revealed 
no interaction of this amino acid with PfCRT 7G8 (Fig. 4d). We also assayed for Arg as a 
potential transported substrate for PfCRT. Like CQ, [3H]-Arg uptake in proteoliposomes 
required a pH gradient and a rY (Extended Data Fig. 10b), and its accumulation peaked 
within one minute (Fig 4e). Scintillation proximity-based binding revealed that [3H]-Arg binds 
to PfCRT 7G8 (Extended Data Fig. 10c), with a half-maximal binding constant of ~400 µM 
(Extended Data Fig. 10d). Binding of [3H]-Arg was effectively competed by both CQ and PPQ, 
as well as by amodiaquine and non-radiolabeled Arg or Lys. In contrast, the aliphatic amino acid 
Leu failed to inhibit [3H]-Arg binding (Extended Data Fig. 10e). Binding of [3H]-Arg, [3H]-CQ 
and [3H]-PPQ was competed by the Fab in a concentration-dependent manner (Fig. 4f), 
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indicating overlapping binding of Arg, CQ, PPQ and the Fab to the PfCRT cavity. In our 
proteoliposome uptake assays, we also observed partial to strong inhibition of [3H]-CQ and [3H]-
Arg uptake by verapamil and 4-aminoquinolines, at levels similar to those observed in the 
binding assays (Fig. 4g and Extended Data Fig. 10e). These data further implicate a crucial role 
for the central cavity in dictating PfCRT 7G8-mediated binding and transport.  
In summary, our 3.2 Å resolution cryo-EM structure reveals that mutations previously identified 
to be involved in antimalarial drug resistance surround a central cavity, implicating this as the 
likely site of parasite protein interaction leading to resistance to these drugs. Moreover, we show 
that PfCRT mediates binding and transport of the 4-aminoquinoline CQ and positively charged 
amino acids in the presence of both membrane potential and pH gradients as driving forces. Our 
binding data and mutational analysis also support emerging PfCRT mutations as drivers of high-
grade PPQ resistance. These results create new tools and perspectives to further elucidate PfCRT 
function and its relation to drug binding and transport, and to assess whether inhibition of PfCRT 
itself can be leveraged as a strategy to overcome its ability to mutate and mediate parasite 
resistance to first-line antimalarial drugs.  
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Figure 1 | Single-particle cryo-EM structure of PfCRT 7G8. a, PfCRT (PlasmoDB ID 
PF3D7_0709000) is localized within the membrane of the P. falciparum intra-erythrocytic 
parasite’s digestive vacuole (DV), wherein imported host hemoglobin (Hb) is catabolized and 
toxic free heme is released. The related 4-aminoquinoline antimalarial drugs chloroquine (CQ) 
and piperaquine (PPQ) are believed to bind heme and prevent its incorporation into inert 
hemozoin9, 14. PfCRT is thought to efflux CQ out of the DV into the cytosol away from its heme 
target. b, Topology of PfCRT with disordered regions shown as dotted lines. Transmembrane 
helices are numbered 1 to 10, while the juxtamembrane helices (JM) are labeled JM1 and JM2. c, 
3.2 Å cryo-EM structure of PfCRT 7G8, with the 10 transmembrane helices colored in rainbow. 
The N- and C- termini are labeled. The right panel shows a 90° rotation with helices numbered, 
as viewed from the DV side. 
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Figure 2 | Structural features of PfCRT. a, Surface representation of the electrostatic potential 
of the central cavity with red and blue being negatively and positively charged, respectively. On 
the right, a central slice through the structure (dotted lines) as an insert shows the arrangement of 
transmembrane helices, which are labeled from N- to C-terminus. b, Interaction between the 
CTC Fab and PfCRT 7G8. PfCRT is rendered in cartoon and colored based on conservation. 
Residues in PfCRT 7G8 that are proximal to R111 in the Fab variable region (pink and red 
arrowed) are colored on the basis of their conservation in our selected panel of Apicomplexan 
parasites (Extended Data Fig. 9 and 10). c, PfCRT and Fab are rendered in cartoon and colored 
in conservation and pink, respectively. d, Cysteine residues that likely form disulfide bonds at 
the region between TM7 and TM8 are shown in yellow and rendered as sticks. 
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Figure 3 | Mapping of mutations onto the PfCRT structure. a, Chemical structures of CQ and 
PPQ. b, Residues known to contribute to resistance to CQ and PPQ have their side chains 
rendered as sticks and are colored based on their resistance profiles. The remaining structure is 
rendered in cartoon and colored in grey. Highlighted residues are topologically represented in 
Extended Data Fig. 1. Mutations in the 7G8 and Dd2 regional haplotypes of PfCRT (Extended 
Data Fig. 1 and Extended Data Table 2) are colored, using the atomic model for the solved 
7G8 structure. 
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Figure 4 | Functional characterization of PfCRT 7G8. a, Binding of 370 nM [3H]-CQ (red) or 
75 nM [3H]-PPQ (blue) to PfCRT 7G8 ± imidazole (Imid.; data are means±SEM; N,n=3,3). b, 
Isotopic dilution of [3H]-CQ (¢) or [3H]-PPQ (q) revealed LogEC50 of -6.53 ± 0.04 M and -
6.70 ± 0.05 M (corresponding to means of 296.5 nM CQ and 189.6 nM PPQ), respectively. c, 
Competition of [3H]-CQ (£) or [3H]-PPQ (s) binding with non-radiolabeled PPQ or CQ, 
respectively, revealed LogIC50 values of -6.77 ± 0.03 M and -6.78 ± 0.06 M (corresponding to 
means of 170.9 nM and 167.3 nM), respectively. d, Specific binding of [3H]-CQ or [3H]-PPQ 
performed in the absence (-) or presence of 10 µM verapamil (VP), 1 µM amodiaquine (ADQ), 
10 µM lumefantrine (LMF) or atovaquone (ATQ), or 1 mM Arg or Leu. Nanodiscs containing 
LeuT29 served as control. e, Time course of 93 nM [3H]-CQ, 75 nM [3H]-PPQ, or 125 nM [3H]-
Arg, uptake measured with 7G8 PfCRT-containing proteoliposomes (PLs). Data are mean±SEM; 
N,n=2,3.  f, Fab binding to the PfCRT 7G8 isoform reduces binding of 250 nM [3H]-Arg, 370 
nM [3H]-CQ, or 75 nM [3H]-PPQ in a concentration-dependent manner, yielding IC50 values of 
0.18 ± 0.02 µM, 0.15 ± 0.02 µM, and 0.20 ± 0.02 µM, respectively. g, One-minute uptake of 370 
nM [3H]-CQ or 250 nM [3H]-Arg was determined in the presence or absence of 1 µM Fab, 10 
µM VP, CQ, PPQ, ADQ, or 1 mM Leu. Data are shown as mean±SEM (N,n=2,3) and values are 
normalized to the signal in the absence of non-radiolabeled compound. Data in panel a, c, d, and 
f are shown as mean±SEM (N,n=3,3) and are normalized to the specific signal (total cpm minus 
cpm in the presence of imidazole) in the absence of the respective non-radiolabeled compound. 
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Small-scale expression screen of CRT variants. Initial expression studies were performed with 
twelve CRT variants, including the Plasmodium falciparum pfcrt sequences 7G8 (AF233064), 
HB3 (Q9N623), HB3 that was codon optimized for Xenopus laevis, Dd2 (D5L5S2), Dd2 codon 
optimized for Xenopus laevis, Plasmodium berghei CRT (PbCRT, Q9GSD8), Plasmodium 
knowlesi CRT (PkCRT, Q9GSD7), Plasmodium vivax CRT (PvCRT, Q9GSD3), PvCRT codon 
optimized for Spodoptera frugiperda, Theileria parva CRT (TpCRT, Q4N5R6), Theileria 
annulata CRT (TaCRT, Q4UDS9), and Cryptosporidium parvum CRT (CpCRT, Q7YZ23). To 
express these in mammalian cells, the sequences were cloned into pFM1.235 as a GFP fusion 
with a decahistidine affinity tag at either the 5’ or 3’ end of the gene. One µg of each construct 
was diluted into 100 µl opti-MEM (ThermoFisher Scientific) and mixed with 100 µl opti-MEM 
containing 4 µg of polyethylenimine (PEI) Max MW 40,000 (Polysciences). This mixture was 
added to 1.0´106 HEK293T cells (Invitrogen) cells in a total volume of 2 mL, in a 6-well plate 
(Corning). The cell transfection mixture was incubated at 37°C for 72 hr in 5% CO2. Transfected 
cells were then harvested, centrifuged at 800´g for 10 minutes at 4°C, and washed once on ice in 
1´PBS. Each pellet was resuspended and solubilized in 20 mM HEPES pH 7.5, 200 mM NaCl, 
20 mM MgSO4, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), cOmpleteÔ, EDTA-free 
Protease Inhibitor Cocktail (Roche), 10 µg/mL DNaseI (Roche) and 8 µg/mL RNase (Sigma-
Aldrich) supplemented with 1% n-dodecyl-β-D-maltopyranoside (DDM) and 0.1% cholesteryl 
hemisuccinate (CHS) at 4°C for 2 hr. Insoluble material was removed by ultracentrifugation in a 
single angle rotor at 4°C for 45 min. The supernatant of each sample was subjected to western 
blot analysis using a rabbit anti-GFP antibody (diluted 1:5,000; Invitrogen) and a secondary goat 
anti-rabbit IgG conjugated to horseradish peroxidase (diluted 1:7,000; Invitrogen). Labeling was 
detected using a western blot Luminol reagent (Santa Cruz).  
Expression and stability were further evaluated by fluorescence-coupled size exclusion 
chromatography (FSEC)36. In these assays, each GFP-tagged construct was transfected into 
HEK293 Freestyle cells (Invitrogen) in the presence of PEI. Transfected cells were incubated at 
37°C for 72 hr with 8% CO2 and 70% humidity. Cell supernatants for the FSEC analysis were 
prepared as described above. DDM-solubilized supernatants were loaded onto a TSKgel 
G4000SWxl column (Tosoh Bioscience LLC) attached to a Prominence UFLC (Shimadzu) 
coupled to a RF-10AXL fluorescence detector (Shimadzu). These studies identified the PfCRT 
7G8 construct as having the best yield and mono-dispersity.  
PfCRT 7G8 protein expression, purification and nanodisc reconstitution. The pfcrt 7G8 full-
length open reading frame was cloned into the pEG BacMam vector37 using the Gibson 
Assembly method38. pfcrt was fused at its 3’ end with a Tobacco Etch Virus (TEV) protease 
cleave site (ENLYFQSYV) and a decahistidine affinity tag followed by a streptavidin affinity 
tag (WSHPQFEK). The resulting plasmid was transformed into DH10Bac E. coli competent 
cells to generate the bacmid using bac-to-bac (Invitrogen) protocol. Recombinant P1 baculovirus 
was transfected into Sf9 cells (Expression System) in the presence of PEI and cultured in ESF 
921 Protein-free insect cell culture medium (Expression Systems). For protein expression, 100 
mL P4 virus was used to infect 1L cultures of HEK293S GnTi- cells (Invitrogen) at 3´106 
cells/mL in Freestyle 293 media (GIBCO) supplemented with 2% FBS (GIBCO). After 
infection, the cells were incubated at 37°C for 8 to 10 hr in the presence of 8% CO2 and 70% 
53
humidity. We then added 10 mM sodium butyrate (Sigma-Aldrich) to enhance BacMam protein 
expression. Cells were incubated at 37°C for another 48 hr prior to their harvest. Cell pellets 
were homogenized in low salt buffer 10 mM HEPES pH 7.5, 10 mM KCl, 10 mM MgCl2, 0.5 
mM PMSF, cOmpleteÔ, EDTA-free Protease Inhibitor Cocktail, 10 µg/mL DNaseI and 8 
µg/mL RNase in a glass homogenizer. Membrane fractions were isolated by ultracentrifugation 
at 40,000´g in Type 45 Ti Rotor (Beckman Coulter). Membrane fractions were further 
homogenized and washed twice with high salt buffer containing 10 mM HEPES pH 7.5, 10 mM 
KCl, 10 mM MgCl2, 1 M NaCl, 0.5 mM PMSF, cOmpleteÔ, EDTA-free Protease Inhibitor 
Cocktail, 10 µg/mL DNaseI and 8 µg/mL RNase in a glass homogenizer followed by 
ultracentrifugation. The washed membrane fractions were resuspended again by homogenizing 
in buffer containing 20 mM HEPES pH 7.5, 200 mM NaCl and 0.5 mM PMSF, and cOmpleteÔ, 
EDTA-free Protease Inhibitor Cocktail, and then stored at -80°C until use. 
The thawed membrane fraction was solubilized by adding DDM with CHS in a 10:1 (w/w) ratio 
to a final concentration of 1% (w/v) detergent and incubating at 4°C for 2 hours with gentle 
agitation. Insoluble material was removed by ultracentrifugation at 40,000´g in a type 45 Ti 
rotor (Beckman Coulter) at 4°C for 30 min. The supernatant was filtered (Millipore) into a 
Falcon tube containing pre-equilibrated Ni2+-NTA resin (Qiagen) in the presence of 20 mM 
imidazole and incubated 4°C overnight with gentle rotation. The resin was washed with 10 
column volumes of buffer containing 20mM HEPES pH 7.5, 200 mM NaCl, 60mM imidazole, 
0.1% DDM and 0.01% CHS and eluted with buffer consist of 20 mM HEPES pH 7.5, 200 mM 
NaCl, 200 mM imidazole, 0.05% DDM and 0.005% CHS. The eluted protein was incorporated 
into lipid nanodiscs with a molar ratio 1:600:10 of protein:1-palmitoyl-2-oleoyl-sn-glycero-3-
phospho-(1'-rac-glycerol) (POPG): membrane scaffold protein 1D1 (MSP1D1) and incubated at 
4°C for 2.5 hr with gentle agitation. Reconstitution was initiated by removing detergent with the 
addition of Bio-beads (Bio-Rad) at 4°C overnight with constant rotation. Bio-beads were 
removed and the nanodisc reconstitution mixture was bound again to Ni2+-NTA resin for at 4°C 
for 2 hr to remove free nanodiscs. The resin was washed with 10 column volumes of wash buffer 
(20 mM HEPES pH 7.5, 200 mM NaCl and 20 mM Imidazole) followed by 4 column volumes 
of elution buffer (20 mM HEPES pH 7.5, 200 mM NaCl and 200 mM Imidazole). The eluted 
protein was further purified by loading on a Superdex 200 Increase 10/300 GL size-exclusion 
column (GE Healthcare Life Sciences) in gel filtration buffer (20 mM HEPES pH 7.0 and 150 
mM NaCl).  
Identification of PfCRT-specific Fab fragments using phage display. For the purposes of Fab 
screening, PfCRT 7G8 was reconstituted into nanodiscs using biotinylated MSP1D1. Prior to 
nanodisc assembly, MSP1D1 was chemically biotinylated as previously described16, 39, 40. 
Efficient biotinylation was confirmed using a pull-down assay with streptavidin-coated 
paramagnetic particles (Promega). Biopanning was performed using Fab Library E41, 42 in 
Selection Buffer (25 mM HEPES pH 7.4, 150 mM NaCl, and 1% Bovine Serum Albumin). In 
the first round, biopanning was performed manually using 200 nM of PfCRT 7G8-MSP1D1 
nanodiscs immobilized onto magnetic beads. Following three washes with Selection Buffer, the 
resuspended beads enriched for PfCRT-specific Fab fragments were used to infect log-phase E. 
coli XL-1 Blue cells. Phages were amplified overnight in 2xYT media supplemented with 
ampicillin (100 µg/mL) and M13-KO7 helper phage (109 pfu/mL). To increase the stringency of 
selection, four additional rounds of sorting were performed with decreasing target concentration, 
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from 150 nM to 75 nM to 40 nM to 20 nM. For each round, the amplified phage pool from each 
preceding round was used as the input. For rounds 2-5, biopanning was performed semi-
automatically using a Kingfisher magnetic beads handler (Thermo Fisher Scientific). To reduce 
the presence of non-specific binders, the phage pool for rounds 2-5 was pre-cleared with 100 µL 
of streptavidin particles. Moreover, for all rounds empty, non-biotinylated 1D1 nanodiscs were 
used as soluble competitors in excess at a constant concentration of 1.5 µM. Finally, in rounds 2-
5, bound phage particles were removed by elution from magnetic beads following a 15 min 
incubation step with 1% Fos-choline-12 prepared in Selection Buffer.  
Single-point phage ELISA. The initial validation for selection was performed by single-point 
phage ELISA using individual clones from rounds 4 and 5. All ELISA experiments were 
performed in 96-well plates (Nunc) coated with 2 µg/mL Neutravidin and blocked with Selection 
Buffer. Colonies of E. coli XL-1 blue harboring phagemids were used to inoculated 400 µL 
2xYT media supplemented with 100 µg/mL ampicillin and 109 pfu/mL M13-KO7 helper phage. 
Phages were amplified overnight in 96-well deep-well blocks at 37°C with shaking at 280 rpm. 
Amplified phages were diluted 10-fold into Selection Buffer and assayed against either PfCRT-
loaded or empty biotinylated nanodiscs. Target proteins were immobilized at room temperature 
for 30 min followed by incubation with phage dilutions for 30 min. Bound phage particles were 
detected with TMB substrate (Thermo Fisher Scientific) following a 30 min incubation with 
HRP-conjugated anti-M13 monoclonal antibody (GE Healthcare). The reaction was quenched 
with 1.0 M HCl and the absorbance at 450 nm was measured. Wells containing empty nanodiscs 
were used to determine non-specific binding.  
Fab expression and purification. Specific binders from phage ELISA were selected based on 
their signal/background ratio16 and were sequenced at the University of Chicago Comprehensive 
Cancer Center DNA Sequencing facility. Unique clones were then sub-cloned in pRH2.2 using 
the In-Fusion Cloning kit (TaKaRa Bio). Sequence-verified Fab expression vectors were then 
transformed into E. coli BL21-Gold competent cells (Agilent) and used to inoculate overnight 
cultures. Inocula were used the following morning to seed 1L 2xYT broth supplemented with 
100 µg/mL ampicillin, which were subsequently grown to an OD600 of 0.8 and then induced for 
4 hours. Cells were harvested by centrifugation and stored at -80°C until use. Cell pellets were 
resuspended in buffer (20 mM HEPES pH 7.4, 150 mM NaCl and 0.5 mM MgCl2) supplemented 
with 1 mM PMSF and 1 µg/mL DNase I (Gold Biosciences). These preparations were sonicated 
(Branson Sonifier) until complete lysis was achieved. Lysates were then incubated at 60°C for 30 
min to eliminate potential Fab proteolyzed fragments, subsequently cooled on ice, and cleared by 
centrifugation. Supernatants were filtered and then loaded onto a 5-mL HiTrap MabSelect SuRe 
column (GE Healthcare) equilibrated with Wash Buffer (20 mM HEPES pH 7.4 and 500 mM 
NaCl). The column was washed 10 times with Wash Buffer and Fabs were eluted with 0.1 M 
acetic acid. Fractions containing Fab fragments were loaded onto a 1 mL Resource S column 
(GE Healthcare) equilibrated with buffer A (50 mM sodium acetate, pH 5.0). Following washing 
with 10 column volumes of buffer A, Fab fragments were eluted by a linear 0-50% gradient with 
buffer B (buffer A with 2 M NaCl). Fractions containing Fab fragments were evaluated for purity 
by SDS-PAGE and subsequently pooled and dialyzed overnight in 20 mM HEPES pH 7.4 and 
150 mM NaCl.  
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Multi-point protein ELISA. To estimate apparent binding affinity, we performed multi-point 
ELISA with purified Fab fragments16. Purified Fab fragments were diluted serially 3-fold 
starting from 3 µM maximum concentration. ELISA plates were coated and blocked as described 
above for the phage ELISA studies. 50 nM of biotinylated PfCRT 7G8-MSP1D1 nanodiscs were 
immobilized on the plates by 30 min incubation, followed by washing. Fab dilutions were added 
to wells containing immobilized PfCRT and allowed to bind for 30 min. Bound Fab was detected 
with TMB substrate following a 30 min incubation with HRP-conjugated mouse anti-human IgG 
F(ab’)2 monoclonal antibody (Jackson). Reactions were quenched with 1.0 M HCl and the 
absorbance at 450 nm was measured. A450 values were plotted against the log10 of the Fab 
concentration. EC50 values were then calculated in Prism (GraphPad Software) using a variable 
slope model and assuming a sigmoidal dose response. 
PfCRT 7G8 in nanodisc complexed with Fab CTC. Size-exclusion chromatography fractions 
of purified PfCRT in nanodisc were incubated with the CTC Fab on ice for 2 hr in a 1:3 molar 
ratio of protein to Fab. The PfCRT-Fab complex was then concentrated and filtered, and then 
loaded on a Superdex 200 Increase 10/300 GL size-exclusion column in gel filtration buffer 
(20mM HEPES pH 7.0 and 150mM NaCl). 
Negative stain electron microscopy. In order to determine the quality of the sample and success 
of the Fab binding, purified protein was diluted to 0.01 mg/ml (for PfCRT without Fab) or 0.005 
mg/ml (for PfCRT with Fab) and applied onto copper grids (Ted Pella). These grids were 
overlaid by a thin (∼1.5 nm) layer of continuous carbon that had been plasma-cleaned (Gatan 
Solarus) for 30s using a mixture of H2 and O2. Thereafter, filter paper (Whatman 4) was used to 
remove the protein solution. 3 µl of 2% uranyl formate was then added and immediately 
removed by absorbing with filter paper – this repeated seven times. The grid was imaged on 
either a Tecnai T12 microscope (FEI) (for PfCRT without Fab) or a Tecnai TF20 microscope 
(FEI) (for PfCRT with Fab). Both microscopes were equipped with a Tietz F416 CCD camera 
(Tietz) at 1.23 Å or 1.10 Å per pixel respectively, using the Leginon software package43. 166 and 
87 images were collected respectively and were processed using the Appion software package44 
to obtain 2D classes with Relion 2.145, 46. The micrographs showed good particle dispersion 
(Extended Data Fig. 3). 2D class averages showed that the Fab addition resulted in a clear 
fiducial for particle alignment. 
Single-particle cryo-EM vitrification and data collection. Purified PfCRT-Fab complex was 
concentrated to 1.56 mg/ml using a 30-kDa concentrator (Amicon). 2.5 µL of sample was added 
to a plasma-cleaned (Gatan Solarus) 1.2/1.3 µm holey gold grid (Quantifoil UltrAuFoil) and 
blotted using filter paper on one side for 2s using the Leica GP plunger system before plunging 
immediately into liquid ethane for vitrification. The plunger was operating at 6°C with >80% 
humidity to minimize evaporation and sample degradation. 
Data acquisition. Images were recorded on a Titan Krios electron microscope (FEI) equipped 
with a Cs corrector and K2 summit direct detector (Gatan) operating at 0.5175 Å per pixel 
(calibrated using an AAV2 dataset) in counting mode using the Leginon software package43. 
Energy filter slit width of 15 eV was used during the collection and was aligned automatically 
every hour using Leginon. Data collection was performed using a dose of ~91.56 e-/Å2 across 80 
frames (75 msec per frame) at a dose rate of ~4.0 e–/pix/sec, using a set defocus range of -1.2 µm 
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to -1.8 µm. A 100 µm objective aperture was used. In total, 3,377 micrographs were recorded 
over a single 2.5-day collection using an image beam shift data collection strategy47. Ice 
thickness was monitored after every 4th exposure using the Leginon zero-loss peak (ZLP) 
algorithm48 and was determined to be 23.1 ± 9.1 nm (SD) 
Data processing. Movie frames were aligned using MotionCor249 with 3 by 3 patches, a 
grouping of 3, and a B-factor of 100, using the Appion software package44. Micrograph CTF 
estimations were performed using both CTFFind450 and GCTF51, and the best estimates based on 
confidence were selected using the Appion software package. Micrographs that had estimated 
resolution at 0.5 confidence level of worse than 10 Å were removed, resulting in 3,297 
micrographs. DoG picker52 was used to pick 682,520 particles (extracted binned by 2), which 
were transferred into Relion 2.145, 46 for 2D classification. 2D class averages that showed clear 
structural details of PfCRT were used as templates for template-based picking using Gautomatch 
(https://www.mrc-lmb.cam.ac.uk/kzhang/Gautomatch; Kai Zhang, unpublished). To not miss 
any particles, we chose a lenient threshold that resulted in 1,095,304 initial picks. These were 
pared down to 183,241 particles after Relion 2D classification. Two rounds of CryoSPARC 2 53 
ab initio (using 2 models) were then performed to further refine the particle stack to 35,682 
particles, which yielded an 8.27 Å resolution upon 3D homogeneous refinement. Particles were 
then re-centred and re-extracted using Relion and per-particle CTF estimation using GCTF was 
then performed. The particle stack was brought back into CryoSPARC for one round of ab initio 
refinement (using 2 models). The best set of particles and model was then used for non-uniform 
refinement. This resulted in a 3.7 Å map from 17,034 particles. 
The mag_distortion_correct software54 was then used on the micrographs to correct for 
magnification anisotropy of 1.3%, which was determined previously using gold-replica grating 
using the mag_distortion_estimate software54. The resulting particles were then subjected to 
three rounds of CryoSPARC non-uniform refinement, re-centering and re-extracting in Relion, 
with removal of overlapped particles centered no more than 20 pixels from each other, and CTF 
refinement using cisTEM55. This resulted in 3.6 Å from 17,030 particles. 
In an effort to optimize the alignment of frames, movie frames were re-aligned using 
MotionCor2 with 2 by 2 patches, a grouping of 3, correction for in-frame motion, and a B-factor 
of 150 for global frame alignment and 50 for local frame alignment. Visual inspection of the 
resulting micrographs showed that certain micrographs fared better using the new frame 
alignment parameters (these were less blurry), while some fared worse than with the 3 by 3 
patches described above. To determine the best frame alignment parameter on a per-particle 
basis, particles were extracted from micrographs using both conditions. These particles were then 
subjected to a CryoSPARC 2 non-uniform refinement and one round of cisTEM refinement. 
Thereafter, for each particle, we chose the alignment parameter that produced the highest score. 
This resulted in 7,191 particles coming from micrographs aligned with 2 by 2 patches, and 9,714 
particles coming from micrographs aligned with 3 by 3 patches. Particle polishing algorithms 
that require neighboring particles to aid in alignment were tested but gave consistently worse 
results, likely because of the low average number of particles per micrograph (~5.3) caused by 
the high magnification used and sizeable number of free Fab contaminants. 
Thereafter, signal subtraction using Relion was performed. Subtraction of just the nanodisc did 
not improve the overall resolution. However, subtraction of both the nanodisc and constant 
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domain of the Fab improved the resolution of the reconstruction, after CryoSPARC non-uniform 
refinement, to 3.3 Å overall, and 3.2 Å for PfCRT alone. 
This final map was sharpened using phenix.auto_sharpen56, which automatically selected b_iso 
sharpening to high_resolution cutoff as the algorithm to use. Overall b_sharpen applied was 28.3 
Å2, final b_iso obtained was 47.3 Å2 and the high-resolution cut-off was 3.2 Å. 
All conversions between Relion, CryoSPARC, and cisTEM were performed using Daniel 
Asarnow’s pyem script (unpublished, https://github.com/asarnow/pyem). 
Model building and refinement. To build the PfCRT model, we first used the Chimera57 
program to approximately segment out the PfCRT part of the map from the nanodisc and Fab 
density. De novo model building for the PfCRT cryo-EM map its primary sequence was initiated 
using Rosetta58. After two rounds of Rosetta model building, the partial model was brought into 
Coot59 program for manual model building. For model building of the Fab, the Fab portion of the 
deposited yeast nucleoprotein complex (PDB-ID:4XMM60) was used as a starting template as it 
had the same scaffold backbone. An extra electron density between PfCRT helices 1, 9 and 10 
was not modelled by protein density and was likely of lipid origin. Out of the lipids potentially 
present in the nanodisc, CHS produced the best density fit and was therefore incorporated into 
the model. 
Thereafter, model adjustment and refinement were performed iteratively in Coot and Phenix, 
with the statistics being examined using Molprobity61 until no further improvements were 
observed. The final map and model were then validated using 1) EMRinger62 to compare map to 
model, 2) ResMap63 to calculate map local resolution, and 3) a program suite with 3D Fourier 
shell correlations (FSC; 64). To calculate the FSC values, we used a cut-off criterion of 0.14365. 
The 3D FSC program suite64 was used to calculate the degree of directional resolution 
anisotropy. Map-to-model FSCs were also calculated by first converting the model to a map 
using Chimera molmap function at Nyquist resolution (2.07 Å). A mask was made from this map 
using Relion (after low-pass filtering to 8 Å, extending by 1 pixel and applying a cosine-edge of 
3 pixels), and was then applied to the density map. Map-to-model FSC was calculated using 
EMAN66. 
Model analysis. A cavity search using the Solvent Extractor from Voss Volume Voxelator 
server67 was performed using an outer probe radius of 10 Å and inner probe radius of 3 Å. We 
then used a Dali server68 to search for other PDB structures with a similar fold. This search 
produced top results for Vrg4 (PDB ID: 5OGE/5OGK;17), YddG (PDB ID: 5I20;18) and TPT 
(PDB ID: 5Y78/5Y79;19), with Z scores from 26.7 to 16.0. Thereafter, there was a large drop in 
Z score for the next best hit at 8.5 (the chloride pumping rhodopsin, PDB ID: 5B2N) that 
visually did not superimpose well with PfCRT (Root mean square deviation of superimposition 
was 8.1 Å). 
Amino acid sequence alignments. For conservation analysis in Apicomplexan parasites, we 
obtained nine orthologs of CRT from OrthoMCL-DB69. Their amino acid sequences were then 
aligned using MUSCLE70.  
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For the pairwise alignments shown in Extended Data Fig. 6, the PfCRT 7G8 sequence was 
trimmed of residues 1-50 (N-terminus and JM1), 181-202 (TM5), 262-303 (JM2) and 368-424 
(TM10 and C-terminus) and put through the AlignMe71-73 server. 
For the sequences used for Extended Data Fig. S8, the sequences used are Pf3D7_0709000, 
PVX_087980, PKNH_0107600, PY05061, PBANKA_1219500, PCHAS_1220200, Chro.60564, 
cgd6_4890, and TA12005. Multiple sequence alignments were displayed using ESPript74. 
Scintillation proximity assay (SPA)-based binding. All radiolabeled compounds were 
purchased from American Radiolabeled Chemicals. Unless other concentrations are indicated, 
binding of 125 nM [3H]-Arg (40 Ci/mmol), 370 nM [3H]-CQ (5.45 Ci/mmol), or 75 nM [3H]-
PPQ (15 Ci/mmol) (unless was performed with the SPA, as described previously24. 100 ng of 
PfCRT 7G8 reconstituted into nanodiscs were assayed in buffer composed of 50 mM Tris/Mes, 
pH 7.5, 5 % glycerol, 0.1 mM TCEP, 0.1 % PEI in the presence of 125 µg of YSi-His Tag SPA 
beads (Perkin Elmer), and in the presence or absence of indicated reagents or Fab. 800 mM 
imidazole, which competes with the His tag (fused to PfCRT) for binding to the copper-coated 
YSi SPA beads, was used to determine the non-proximity background signal. Concentrations of 
radiolabeled compounds were chosen in pilot experiments to obtain a signal-to-noise ratio ≥ 5, 
and specific binding was determined by subtracting the cpm in the presence of imidazole from 
the cpm measured in its absence. Control binding experiments of [3H]-CQ employed nanodiscs 
containing 100 ng of the unrelated Aquifex aeolicus bacterial amino acid transporter LeuT. Non-
linear regression analysis of the data was performed with GraphPad Prism 7. Kinetic constants 
represent the means ± SEM of the fit.  
Transport measurements. Purified PfCRT 7G8 was reconstituted in preformed liposomes made 
of E. coli total lipids:CHS 94:6 (w/w) at a protein-to-lipid ratio of 1:150 (w/w). The lumen of the 
proteoliposomes was composed of 100 mM KPi, pH 7.5 and 2 mM β-mercaptoethanol. Uptake of 
[3H]-Arg (40 Ci/mmol), [3H]-CQ (5.45 Ci/mmol), or [3H]-PPQ (15 Ci/mmol) was performed by 
diluting PfCRT-containing proteoliposomes (40 ng PfCRT per assay) in 50 µL of 100 mM 
Tris/Mes, pH 5.5. When indicated, 1 µM valinomycin (Val) was added to the reaction to 
generate a K+ diffusion potential-driven membrane potential. The reactions were stopped after 
the indicated time periods by the addition of ice-cold 100 mM KPi, pH 6.0/100 mM LiCl and 
filtered through 0.45 µm nitrocellulose filters (Millipore). Filters were dried and incubated in 
scintillation cocktail, and the radioactivity captured on the filters was counted in a Hidex SL300 
scintillation counter. Specific radioactivity of all compounds was confirmed by counting known 
amounts of each radiolabel by determination of the decays-per-minutes (dpm) to transform the 
dpm of the samples into pmol. Unspecific binding of all compounds with the nitrocellulose 
filters was determined by measuring mock uptakes in the absence of liposomes or 
proteoliposomes, and these values (determined for each experiment) were used to calculate the 
uptake activity in liposomes or proteoliposomes. For data shown in Extended Data Fig. 13, the 
specific uptake was determined by subtracting the time-dependent accumulation of the tested 
compounds in control liposomes (lacking PfCRT) from that measured in PfCRT-containing 
proteoliposomes.  
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Extended Data Figure 1 | Major PfCRT haplotypes and location of residues involved in 
chloroquine (CQ) or piperaquine (PPQ) drug resistance phenotypes. a, Listing of the PfCRT 
canonical CQ-sensitive 3D7 haplotype, the 7G8 (South America and Western Pacific) and Dd2 
(Southeast Asia) variant haplotypes, and mutations that have emerged in P. falciparum parasites 
in malaria-endemic areas that contribute to PPQ resistance. b, Localization of PfCRT mutations 
associated with CQ or PPQ resistance, based on the solved PfCRT structure. Most mutations 
localize within or near the boundary of one of the 10 transmembrane helices. JM, 
juxtamembrane. Extended Data Table 2 shows an expanded list of mutations observed in the 
field or obtained in drug-pressured cultured parasites. 
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Extended Data Figure 2 | Identification of PfCRT-specific antigen-binding fragments (Fab) 
and preparation of purified PfCRT±Fab protein in nanodiscs. a, Complementarity-
determining region (CDR) sequences of unique antigen-binding fragments (Fabs) panned for 
binding to recombinant PfCRT incorporated into MSP1D1 nanodiscs. Fabs were selected 
following multiple rounds of enrichment from the phage display library E41, 42, 75. Enriched 
SYGW residues are highlighted by color code (red, yellow, green and blue, respectively) and are 
numbered according to the Kabat system76. b, Single-point ELISA quantifying the binding of 
phage-displayed Fab to PfCRT-incorporated nanodiscs, empty nanodiscs, or buffer (empty 
wells), as measured at 450 nm absorbance. c, EC50 evaluation for purified Fab binding to PfCRT 
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incorporated into biotinylated nanodiscs, showing high affinity binding for the CTC Fab (3.7 
nM). d, High-performance liquid chromatography profile of PfCRT ± bound CTC Fab. e, SDS-
PAGE gel of pooled and concentrated size-exclusion chromatography fractions from 
PfCRT±CTC Fab. The contaminant glutamate dehydrogenase, GDH (present as a left shoulder in 
d), was excluded from single-particle analyses. MSP1D1 is a membrane scaffold protein used to 
assemble the nanodiscs. The identity of PfCRT and GDH was confirmed using mass 
spectrometry. 
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Extended Data Figure 3 | Negative-stain electron microscopy of PfCRT with and without 
Fab. a, Representative micrograph and 2D class averages from Relion45 2D classification of 
nanodisc-incorporated PfCRT without Fab. b, Representative micrograph and 2D class averages 
from Relion 2D classification of nanodisc-incorporated PfCRT with bound CTC Fab. 
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Extended Data Figure 4 | Cryo-EM analysis of the PfCRT-Fab complex. a, Representative 
micrograph (0.5175 Å per pixel, 1.65 µm defocus). Picked particles contributing to the final 
reconstruction are circled in green. b, Representative 2D class averages from Relion 2D 
classification. c, Euler angle distribution plot of the final 3D reconstruction from CryoSPARC 
253. d, Fourier shell correlation (FSC) curves for PfCRT complexed with the Fab variable
domain as well as for PfCRT alone. Data show the half-map (blue) and map-to-model (purple)
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resolutions (at 0.143 and 0.5 cut-offs respectively), with embedded histograms of directional 
resolutions sampled evenly over the 3D-FSC64 (yellow). The corresponding sphericity values are 
indicated. e, Local resolution77 display of unsharpened reconstructions of PfCRT complexed 
with the Fab variable domain, in orthogonal views, sliced through the density. 
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Extended Data Figure 5 | Fit of cryo-EM density with model. Cryo-EM densities (mesh) are 
superimposed with TM and JM helices of the PfCRT model. The model is rendered as a cartoon, 
colored in rainbow. 
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Extended Data Figure 6 | Symmetrical arrangement in inverted topology repeats of PfCRT. 
a, View of PfCRT from opposite directions of the DV and cytoplasm, with labeling of the four 
helices that are closest to the center (thus contributing to the cavity). b, AlignMe71-73 sequence 
alignment between the two structural repeats within this pseudo-symmetric transporter reveals a 
high degree of sequence conservation, with each helix lining up with its corresponding helix 
from the pseudo-repeat. Residues 1-50 (N-terminus and JM1), 181-202 (TM5), 262-303 (JM2) 
and 368-424 (TM10 and C-terminus) were removed when doing the alignment. Helices are 
colored as per Fig. 1. 
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Extended Data Figure 7 | Structural comparison of PfCRT with other DMT superfamily 
members. a, Structural conservation of PfCRT compared with its DMT family members Vrg4 
(PDB ID: 5OGE;17), YddG (PDB ID: 5I20;18) and TPT (PDB ID: 5Y78;19), generated using the 
Dali server68. b, Electrostatic representation of slices revealing the cavities of these four proteins 
in their solved structural states. Note the highly negatively charged (red) residues in the PfCRT 
cavity, contrasting with the positively charged (blue) or neutral residues in the other DMT 
transporters. Ligands for the non-PfCRT transporters are shown in a ball and stick 
representation.   
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Extended Data Figure 8 | Sequence alignment and secondary structure of PfCRT. 
Sequences of different PfCRT isolates and other CRT homologs aligned using MUSCLE70 and 
displayed using ESPript74. Sequences of nine orthologs of CRT in other Plasmodium or other 
Apicomplexan parasites were obtained from OrthoMCL-DB69. The sequences used are 
Plasmodium falciparum PfCRT strain 3D7 (the canonical wild-type sequence; UNIPROT 
Q9N623), P. chabaudi CRT strain chabaudi (PcCRT, Q7Z0V9), P. yoelii CRT strain 17XNL 
(PyCRT; Q7REK3) P. berghei CRT strain ANKA (PbCRT, Q9GSD8), P. vivax CRT strain Sal-
1 (PvCRT, Q9GSD3), P. knowlesi CRT strain H (PkCRT; Q9GSD7); Theileria annulata CRT 
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strain Ankara (TaCRT, Q4UDS9); Cryptosporidium hominis CRT strain TU502 (ChCRT; 
RefSeq XP_666698); Cryptosporidium parvum strain Iowa II (CpCRT; XP_627815). The 
secondary structure of PfCRT is shown as a cartoon above the alignments, along with the 
positioning of the variant residues indicated in Extended Data Fig. 1 (with same color scheme). 
The cysteine residues that likely form disulfide bonds are shown as green colored numbers below 
the alignment. Residues conserved (i.e. identical or similar) in at least 6 of 9 species are 
indicated in bold red text. Residues conserved in all species are in white text with red 
highlighting. None of the mutations associated with CQ or PPQ resistance mapped to residues 
that are fully conserved. 
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Extended Data Figure 9 | Binding cleft of cholesterol hemisuccinate (CHS) in PfCRT. a, A 
cleft formed by JM1, TM1, TM 9 and TM10 in the PfCRT demonstrates the binding of CHS 
(colored in olive green) in the PfCRT. PfCRT is colored based on conservation. b, PfCRT is 
rendered as surface colored by hydrophobicity, from orange (hydrophobic) to blue (hydrophilic). 
c, 2D diagram of CHS-PfCRT interaction generated using LigPlot+78. 
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Extended Data Figure 10 | Binding and Transport Assays for PfCRT 7G8. a and b, one 
minute uptake for (a) 370 nM [3H]-CQ or (b) 250 nM [3H]-Arg were determined with PfCRT 
7G8-containing proteoliposomes preloaded with 100 mM KPi, pH 7.5 diluted in buffer 
composed of 50 mM Tris/MES, pH 5.5 or 7.5 ± the K+ ionophore valinomycin (5 µM). The 
valinomycin (Vlm)-mediated K+ efflux proceeding down its concentration gradient generated an 
inside-negative membrane potential. Empty liposomes lacking PfCRT 7G8 served as controls. 
Data are mean±SEM (N,n=2,3). c, Total binding of 125 nM [3H]-Arg to 100 ng of nanodisc-
incorporated PfCRT 7G8 was measured in the absence (-) or presence (+) of 800 mM imidazole 
(which competes with the His-tagged PfCRT 7G8 isoform for binding to the copper-coated YSi 
SPA beads). Data are mean±SEM (N,n=3,3). d, Isotopic dilution of 125 nM [3H]-Arg with non-
radiolabeled Arg revealed a LogEC50 value of -3.401 ± 0.03254 M (corresponding to 397.2 µM). 
We note that the primary source of Arg in parasitized red blood cells (RBCs) is from the 
proteolysis of Hb, which in its native state as a tetramer is present at 5 mM in RBCs79. e, Binding 
of 125 nM [3H]-Arg in the presence or absence of 10 µM verapamil (VP), 1 µM CQ or PPQ, 0.1 
µM amodiaquine (ADQ), or 1 mM Arg, Lys or Leu. Data in panels d and e are shown as 
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Chapter 4 ON-GOING STUDIES AND FUTURE DIRECTIONS 
4.1 Introduction 
The structure of PfCRT 7G8 is a powerful tool that can be used to study the molecular 
determinants of anti-malarial drug binding and transport mechanisms. It also provides a 
structural basis for the investigation of clinical drug resistance and allows for greater 
understanding and foresight in the emerging global resistance landscape. We integrated 
structural, functional, and genetic approaches of three laboratories at Columbia  
University Irving Medical Center (Mancia lab, Fidock lab and Quick lab) to establish a 
transformative platform to study PfCRT at the molecular and atomic levels. These developments 
were made possible by the heterologous expression and purification of different PfCRT 
isoforms, Fab technology, and cryo-EM based structural studies. We now can biochemically 
characterize substrate binding and transport properties in purified or liposome reconstituted 
forms of PfCRT and test hypotheses about resistance conferring mutations and their drug 
susceptibility in genetically edited Pf cultures. 
Here, I will discuss how we can leverage our recent structure to further study the 
molecular interactions of PfCRT and the mechanism of antimalarial drug resistance. I will 
describe both ongoing and long-term goals.  
4.2 Investigating the physiological function of PfCRT 
The structural and functional studies of PfCRT CQ-resistant 7G8 isoform reveal that an 
arginine is a putative substrate in CQ-resistant isoforms which is consistent with data in previous 
literature [56].   Based on our observation that arginine is a possible substrate, we performed a 
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scintillation-based proximity assay (SPA) on the purified PfCRT 7G8 reconstituted into 
nanodiscs probed with radiolabeled arginine in the absence or presence of other amino acids to 
see what other amino acids might display binding interaction. Binding of [3H]-Arg was 
competitively inhibited in the presence of non-radiolabeled arginine, lysine and glutamate 
(Figure 4.1) suggesting that these three amino acids are likely to interact with PfCRT 7G8. 
Based on the observation in which arginine in the hypervariable region of the CTC Fab 
stabilizing the PfCRT 7G8-CTC Fab complex, we initially hypothesized that positively charged 
substrates may interact with PfCRT CQ-resistant isoforms. Data showing interaction of arginine 
and lysine with PfCRT are consistent with this proposition. However, glutamate interactions with 
the protein were unexpected.  
Glutathione, a molecule made of three amino acids L-γ-glutamate, L-cysteinyl and 
glycine, is a cellular antioxidant that has been implicated in CQ resistance by which higher 
cellular levels of glutathione enhance CQ resistance [66].  There are two possible explanations 
on the association between glutathione and CQ response [105]. First, the glutathione could 
reduce the accumulation CQ, by which glutathione binds to heme and thus prevents from CQ 
binding to heme. Second, glutathione might encounter the oxidative damage resulted in heme 
degradation, from which Plasmodium parasites could possibly become more resistant to CQ 
[105]. However, there is no definitive understanding of the relationship between glutathione and 
CQ resistance. Strikingly, glutathione diminished the bindings of both Arg and CQ in its reduced 
form (GSH) and completely inhibited their bindings in its oxidized form (GSSG) (Figure 4.1). 
This finding raises a possibility that glutathione could be a natural substrate for PfCRT, and 
further implicates PfCRT has an important role in drug resistance. Our results are consistent with 
the previous hypothesis in that glutathione could be a natural substrate for PfCRT under 
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physiological condition [67] and may be a peptide transporter [55, 56]. To further explore the 
role of PfCRT with glutathione, we will measure the transport activity of glutathione in our 
proteoliposome experiment using radiolabeled GSH and GSSG.    
Figure 4.1 Substrates of PfCRT 7G8 isoform. (a) Binding of [3H]-Arg was competitively inhibited in 
the presence of non-radiolabeled various amino acids as well as both reduced and oxidized glutathione. 
(b) Binding of [3H]-CQ was competitively inhibitied in the presence of glutathione in both reduced and
oxidized forms.
PfCRT may also be involved as a redox sensor because it has four highly conserved 
cysteine residues in a loop extending to the DV between TM 7 and 8 which are likely to form 
two disulfide bonds (C289-C312 and C301-C309). However, the effects of a potential redox 
system of PfCRT in parasites remains unknown. To test whether this conserved region of 
cysteine residues is involved in the reodox capabilities of PfCRT, I have made two single 
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mutants (C289A and C301A) using site-directed mutagenesis. Also, I plan to make double 
mutant (C289 301A) to disrupt both disulfide bonds and investigate whether the mutants affect 
the transport activity of CQ or PPQ in either reduced or oxidized environments.   
4.3 Elucidating the mechanism of PfCRT-mediated drug resistance 
The structure of PfCRT 7G8 provides insights to investigate novel mutations that could 
arise to confer resistance to antimalarial drugs and define their impact on PfCRT-mediated drug 
transport. As discussed in Section 1.6, recently emerged mutations (H97Y, F145I, M343L and 
G353V in the Dd2 isoform and C350R in the 7G8 isoform) that confer resistance to PPQ while 
sensitizing CQ [39, 63] are located around the central cavity in our PfCRT 7G8 structure. To 
gain a better understanding of the functional characterization of drug resistant variants, we have 
created the F145I and C350R mutants in the 7G8 background using site-directed mutagenesis, 
and also expressed and purified CQ-sensitive wildtype HB3 and CQ-resistant Dd2 isoform in the 
same conditions as that of 7G8 described in the Methods section of manuscript in Chapter III for 
the measurement of binding and transport (Figure 4.2). To assess the impact of new mutations in 
drug resistance and transport mechanisms, we measured the efflux of radiolabeled CQ, PPQ, and 
Arg on the purified and reconstituted PfCRT variants into proteoliposome (Figure 4.3). 
Consistent with pfcrt edited Pf cultured lines [39, 63], both F145I and C350R mutants in a 
heterologous expression system reversed CQ transport while mediating the efflux of PPQ. This 
data implicates altered transport as the core feature driving isoform-specific resistance.  
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Figure 4.2 Purification of PfCRT variants. (a) Size-exclusion chromatography profiles of PfCRT 7G8, 
Dd2, HB3, 7G8 C350R, and 7G8 F145I nickel purified in DDMCHS and loaded onto Superdex 200 
Increase 5/150 column. (b) Size-exclusion chromatography profiles of PfCRT variants reconstituted into 
nanodiscs. 
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Figure 4.3 PfCRT variants uptake assay. One-minute uptake of 100 nM [3H]-CQ, [3H]-PPQ, or [3H]-
Arg was measured with PfCRT variants (7G8, Dd2, HB3, 7G8 C350R, and 7G8 F145I) reconstituted into 
proteoliposomes (PLs). Empty lipsome was served as a control. 
4.4 Determining the structures of PfCRT 7G8 in complex with CQ and PPQ 
Our PfCRT 7G8 structure displays a deep central cavity proposed as a putative ligand 
binding site, and we aim to obtain a structure of PfCRT 7G8 in complex with CQ and/or PPQ. 
However, the CTC Fab we used for our initial structural determination appears to compete with 
both CQ and PPQ. Therefore, we are currently reselecting new Fabs following the same Fab 
selection protocol in the presence of a saturation concentration of CQ or PPQ. So far, we have 
obtained 6 new Fabs (PTC #1, 2, 3, 4, 8, 11) using a phage display library from the Kossiakoff 
laboratory which seem to form complexes with PfCRT 7G8 while not interfering with CQ/PPQ 
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binding as shown by a shift during size-exclusion chromatography and from a SPA experiment 
respectively (Figure 4.4). The immediate next steps would be to screen the complex formation 
between PfCRT 7G8 and each Fab in cryogenic conditions with a FEI Tecnai F20 screening 
microscope in order for us to obtain a stable PfCRT-Fab complex and proceed in structural 
characterization of a drug bound state. 
Figure 4.4 PfCRT 7G8 complex with PTC Fabs in the presence of drugs. (a) Size-exclusion 
chromatography profiles of PfCRT complexed with PTC Fabs selected from the screen of phage display 
library in the presence of saturated drug concentration. PfCRT in nanodisc sample was incubated with 
each Fab with 1:3 molar ratio and then loaded on to Superdex 200 Increase 5/150 column. Orange arrow 
indicates PfCRT±Fab. (b) Binding of 100nM [3H]-CQ or [3H]-PPQ was tested in competition with the 
presence of Fabs (PTC1, 2, 3, 4, 8, 11 and 7G1). 
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Figure 4.5 Competition binding assay between CQ and mouse monoclonal antibody Fabs. 
Competition of 370 nM [3H]-CQ binding with Fabs generated from mice by Ilya Trakht. CTC Fab 
occupies the central cavity based on our initial structure of PfCRT 7G8 and was served as a control. 
In parallel, we have been collaborating with Ilya Trakht in the Department of Medicine at 
Columbia University Irving Medical Center who generated mouse monoclonal antibody Fab 
fragments for PfCRT. We obtained four candidates (3G3, 3H10, 11E8 and 7G1) that form 
complexes with PfCRT 7G8, and biochemically tested whether each Fab competes with CQ 
binding (Figure 4.5). In results, we formed PfCRT 7G8-3H10 complex in the presence of CQ 
and collected images on the Titan Krios microscope at New York Structural Biology Center 
using the same parameters as the data collection that yielded our initial structural model. 
However, the dissociation between the protein and the Fab precluded us from obtaining a high 
enough number of particles to achieve a high-resolution density map.  Still, the low-resolution 
density map allowed us to fit our initial model and we have learned that 3H10 Fab binds to the 
loop between TM 7 and 8 (Figure 4.6). 
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Figure 4.6 Cryo-EM analysis of the PfCRT+3H10 Fab complex. (a) Representative 2D class averages 
from Relion 2D classification. (b) Fit of the PfCRT+CTC Fab structural model into a low resolution cryo-
EM density map of the PfCRT+3H10 Fab complex. The PfCRT 7G8 model is rendered as a cartoon and 
colored in rainbow. The CTC Fab is colored in pink. Low resolution density map of the PfCRT+3H10 
complex shown in emerald green. (c) Close up view of electron density map indicating where 3H10 Fab 
interacts with the PfCRT 7G8. 
As a third pathway to find the drug bound state, I am currently engineering a PfCRT 
fusion construct with apocytochrome b562RIL (BRIL) domain [106] to extend the TM 10 based 
on our structural information, as the Kossiakoff lab at University of Chicago can provide us with 
anti-BRIL Fab to form a complex of PfCRT 7G8-BRIL with anti-BRIL Fab. BRIL has been used 
as a GPCR fusion protein to facilitate crystallization by extending hydrophilic surfaces which 
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promotes the formation of stable crystal contacts [106]. This could allow us to make the central 
cavity accessible for CQ or PPQ while the complex would be in the amenable size for cryo-EM 
analysis. A potential limitation of this approach is that extending the TM 10 helix with the BRIL 
domain could introduce structural flexibility hampering us from obtaining a high-resolution 
structure.  
Defining the residues that interact with CQ and/or PPQ will enable us to predict novel 
mutations that could drive antimalarial resistance in geographically diverse PfCRT isoforms. As 
these mutations possibly evolve around the core or the entrance of the central cavity without 
affecting highly conserved residues across Apicomplexan CRT orthologs, we can perform 
molecular dynamic (MD) simulations and docking experiments to mutate these residues to 
investigate the changes in drug interaction. Based on MD simulations and docking scores, we 
can provide further experimental validation by examining both binding and transport of drugs on 
purified mutants. Based on the MD simulations and docking scores, we can then validate 
experimentally by examining both binding and transport of drugs on purified mutants.  
4.5 Determining the structure of PfCRT 7G8 in other conformations 
As with other DMT proteins, PfCRT consists of two inverted topology repeats, TM1-
TM4 and TM6-TM9, suggesting that it is likely to have a similar alternating-access transport 
mechanism. To elucidate the mechanistic basis of PfCRT-mediated transport, we will attempt to 
capture and stabilize an outward-open conformation and other possible intermediate 
conformations. We will attempt to combine our Fab technology mentioned above with a random 
spherically constrained (RSC) single-particle cryo-EM approach, in which the PfCRT-Fab 
complex will be reconstituted into a uniformly sized liposome and frozen on a grid for EM 
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analysis. This method has been used to study the large conductance voltage- and calcium-
activated potassium (BK) channels [107, 108].  
Alternatively, we will also employ crosslinking and cysteine accessibility assays to 
determine the structure of the alternate conformation using the same Fab technology mentioned 
above. We propose to design various combinations of double cysteine mutants near the opening 
of PfCRT on the DV side. This approach has been used to investigate the mechanism of other 
transporters [109]. Both random spherically constrained single-particle cryo-EM and the 
crosslinking experiment could facilitate PfCRT transitioning from the inward to outward open 
state, allowing us to elucidate the mechanistic basis of how a substrate or drug is transported 
across the DV membrane. 
4.6 Conclusions 
PfCRT is an important molecule that mediates drug resistance in malaria. We present the 
structure of PfCRT with a putative binding site for antimalarial drugs, and provide evidence that 
drug resistance is associated with transport mechanism. Determining structures of PfCRT in 
complex with CQ and/or PPQ as well as in other conformations will be crucial to further 
elucidate the mechanism of CQ and/or PPQ resistance.   
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